Deep Learning Paradigm for Cardiovascular Disease/Stroke Risk Stratification in Parkinson’s Disease Affected by COVID-19: A Narrative Review

Jasjit S. Suri 1,*, Mahesh A. Maindarker 1,2, Sudip Paul 2, Sujit Dutta 3, Devendra Chhabra 4, Sanjay Saxena 5, Inder M. Singh 1, Paramjit S. Chadha 1, Monika Turk 6, Amer Johri 7, Narendra N. Khanna 8, Klaudiva Viskovic 9, Sofia Mavrogeni 10, John R. Laird 11, Martin Miner 12, David W. Sobel 13, Antonella Balestrieri 14, Petros P. Sifakis 15, George Tsoufalias 16, Athanase D. Protagoreou 16, Durga Prasanna Misra 17, Vikas Agarwal 17, O. George D. Kitas 18,19, Raghu Kolluri 20, Jagjit S. Teji 21, Mustafa Al-Maini 22, Surinder K. Dhanjal 1, M. Meyyappan Sockalingam 23, Ajit Saxena 8, Aditya Sharma 24, Vijay Rathore 25, Mostafa Fatemi 26, Azra Aliзад 27, Padukode R. Krishnan 28, Tomaz Omerzu 6, Subbaram Naidu 29, Andrew Nicolaides 30, Kosmas I. Paraskevas 31, Manndeep Kalra 32, Zoltán Rusza 33, and Mostafa M. Fouda 34.

1 Stroke Monitoring and Diagnostic Division, AtheroPoint™, Roseville, CA 95661, USA; mahesh.nehu.333@gmail.com (M.A.M.); drindersingh1@gmail.com (I.M.S.); pomchadha@gmail.com (P.S.C.); surinderdhani@gmail.com (S.K.D.)
2 Department of Biomedical Engineering, North Eastern Hill University, Shillong 793022, India; sudip.paul.bhu@gmail.com (S.P.); bhagawatimrinalini07@gmail.com (M.B.)
3 Max Institute of Cancer Care, Max Super Specialty Hospital, New Delhi 110017, India; punnee1923@gmail.com (P.N.K.)
4 Department of Radiology, and Pathology, Azienda Ospedaliero Universitaria, 09123 Cagliari, Italy; lucasabamdi@gmail.com (L.S.); gavinofoa@gmail.com (G.F.)
5 Department of CSE, International Institute of Information Technology, Bhuneshwar 751029, India; sanjay@iiit-bh.ac.in
6 Department of Neurology, University Medical Centre Maribor, 2000 Maribor, Slovenia; monika.turk84@gmail.com (M.T.); omerzu.tomaz@gmail.com (T.O.)
7 Department of Medicine, Division of Cardiology, Queen’s University, Kingston, ON K7L 3N6, Canada; amerschedule@gmail.com
8 Department of Cardiology, Indraprastha Apollo Hospitals, New Delhi 110076, India; drnhkanna@gmail.com (N.N.K.); ajitsaxena@hotmail.com (A.S.)
9 Department of Radiology and Ultrasound, University Hospital for Infectious Diseases, 10000 Zagreb, Croatia; klaudija.viskovic@tfm.hr
10 Cardiology Clinic, Onassis Cardiac Surgery Centre, 176 74 Athens, Greece; sophie.mavrogeni@gmail.com (S.M.)
11 Heart and Vascular Institute, Adventist Health St. Helena, St. Helena, CA 94574, USA; lairdjr@ah.org
12 Men’s Health Centre, Miriam Hospital, Providence, RI 02906, USA; martin_miner@brown.edu
13 Rheumatology Unit, National Kapodistrian University of Athens, 157 72 Athens, Greece; dwosobel@gmail.com (D.W.S.); psifakis@med.uoa.gr (P.P.S.)
14 Docs Eye Care Research Lab, Dunedin 9013, New Zealand; antonellabalastrieri@hotmail.com
15 Department of Surgery, Aristotleion University of Thessaloniki, 541 24 Thessaloniki, Greece; tsouflias@gmail.com
16 Cardiovascular Prevention and Research Unit, Department of Pathophysiology, National and Kapodistrian University of Athens, 157 72 Athens, Greece; aprofetog@med.uoa.gr
17 Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India; durgapmrisa@gmail.com (D.P.M.); vikasagri@yahoo.com (V.A.)
18 Academic Affairs, Dudley Group NHS Foundation Trust, Dudley DY1 2HQ, UK; george.kitas@nhs.net
19 Arthritis Research UK Epidemiology Unit, Manchester University, Manchester M13 9PL, UK
20 OhioHealth Heart and Vascular, Mansfield, OH 44905, USA; kolluri.raghu@gmail.com
21 Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL 60611, USA; ajit@mercy-chicago.org
22 Allergy, Clinical Immunology, and Rheumatology Institute, Toronto, ON M5G 1N8, Canada; almaini@hotmail.com
23 MV Centre of Diabetes, Chennai 600013, India; dr shakyku@yahoo.com
24 Division of Cardiovascular Medicine, University of Virginia, Charlottesville, VA 22908, USA; as8ah@hscmail.mcc.virginia.edu
25 Department of Physiotherapy, Kausal Permanente, Sacramento, CA 95823, USA; vijays.s.rathore@kp.org
26 Department of Physiology & Biomedical Engineering, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA; fatemi.mostafa@mayo.edu

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Citation: Suri, J.S.; Maindarker, M.A.; Paul, S.; Ahluwalia, P.; Bhagawati, M.; Saba, L.; Chadha, P.S.; et al. Deep Learning Paradigm for Cardiovascular Disease/Stroke Risk Stratification in Parkinson’s Disease Affected by COVID-19: A Narrative Review. Diagnostics 2022, 12, 1543. https://doi.org/10.3390/diagnostics12071543

Copyright: © 2022 by the authors. License MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Abstract: Background and Motivation: Parkinson’s disease (PD) is one of the most serious, non-curable, and expensive to treat. Recently, machine learning (ML) has shown to be able to predict cardiovascular/stroke risk in PD patients. The presence of COVID-19 causes the ML systems to become severely non-linear and poses challenges in cardiovascular/stroke risk stratification. Further, due to comorbidity, sample size constraints, and poor scientific and clinical validation techniques, there have been no well-explained ML paradigms. Deep neural networks are powerful learning machines that generalize non-linear conditions. This study presents a novel investigation of deep learning (DL) solutions for CVD/stroke risk prediction in PD patients affected by the COVID-19 framework. Method: The PRISMA search strategy was used for the selection of 292 studies closely associated with the effect of PD on CVD risk in the COVID-19 framework. We study the hypothesis that PD in the presence of COVID-19 can cause more harm to the heart and brain than in non-COVID-19 conditions. COVID-19 lung damage severity can be used as a covariate during DL training model designs. We, therefore, propose a DL model for the estimation of, (i) COVID-19 lesions in computed tomography (CT) scans and (ii) combining the covariates of PD, COVID-19 lesions, office and laboratory arterial atherosclerotic image-based biomarkers, and medicine usage for the PD patients for the design of DL point-based models for CVD/stroke risk stratification. Results: We validated the feasibility of CVD/stroke risk stratification in PD patients in the presence of a COVID-19 environment and this was also verified. DL architectures like long short-term memory (LSTM), and recurrent neural network (RNN) were studied for CVD/stroke risk stratification showing powerful designs. Lastly, we examined the artificial intelligence bias and provided recommendations for early detection of CVD/stroke in PD patients in the presence of COVID-19. Conclusion: The DL is a very powerful tool for predicting CVD/stroke risk in PD patients affected by COVID-19.

Keywords: Parkinson’s disease; COVID-19; cardiovascular/stroke risk stratification; deep learning; bias

1. Introduction

Parkinson’s disease (PD) is a progressive neurodegenerative condition characterized by movement impairments. In 1817, British physician James Parkinson described the condition for the first time [1]. PD is characterized by the loss and dysfunction of neurons (nerve cells) in the substantia nigra, a region of the brain. PD is characterized by problems with dopamine pathways, which are cells in the brain that communicate with other neurons by creating dopamine, also called a neurotransmitter [2]. According to data from a variety of studies, the cost of treating and controlling PD is expensive [3]. Western nations have more PD cases than Asian countries. [3,4].

A coronavirus 2 (SARS-CoV-2)-related acute, respiratory distress disease was found in Wuhan, China, in late December 2019 [5,6]. The infection spread fast over the world, resulting in a global coronavirus pandemic in 2020. Between 31 December 2019, and 11 March 2022, there were nearly 450,229,635 cases of COVID-19 reported globally, with around 6,019,085 deaths [7]. PD is found in the elder age group and it has been observed that
PD patients show comorbidities such as diabetes [8], hypertension [9,10], dementia [11,12], chronic kidney, temporomandibular disorder (TMD) [13], and heart problems [14,15], and thus need continuous medical treatment to control the PD. However, due to the coronavirus pandemic, most countries declared a lockdown, and all the medical forces were used to control the spread of the COVID-19.

During the period of lockdown, less importance was given to PD-affected patients, leading to heart attack and stroke in PD patients [16]. The connection between cardiovascular disease (CVD), stroke, and PD with COVID-19 seems particularly important due to several observations. Antibodies against coronavirus were discovered in the cerebrospinal fluid in PD patients more than two decades ago, implying that viral infections may play a role in the neurodegenerative process [11,17].

As per recent studies [18–20], PD increases the risk of heart attack and stroke [21,22]; current study indicates that PD is associated with vascular risk factors such as diabetes and hypertension [23–27]. Thus, CVD/stroke risk early detection becomes even more important during the joint effects of PD with COVID-19, as it increases the risk of mortality [28]. However, during the joint effects, the covariates cause non-linearity between the covariates and the gold standard. Thus, special tools are needed for CVD/stroke risk stratification [4]. Since COVID-19 causes a change in the risk factors in PD patients, we need a self-adjusting system that can automatically estimate the risk of CVD/stroke in PD patients when COVID-19 is triggered [29].

In recent years, it has been seen that artificial intelligence (AI) has played an important role in computer-aided diagnosis [30,31], particularly in the identification and classification of multiple diseases [32–35]. The application of machine learning (ML) has recently been explained to have dominated the field of medical imaging, including diabetes [36,37], cardiovascular disease [38], liver [39], cancers such as thyroid [39,40], vascular screening [41], ovarian [42], prostate [43], risk characterization using coronary and vascular screening [41], and carotid angiography [44]. Many medical imaging modalities are available for imaging, including magnetic resonance imaging (MRI) [45,46], computed tomography (CT) [47], ultrasonography (US) [48], and CT for lung imaging, all of which can illustrate COVID-19 symptoms and lesions [45,46]. It has been shown that the DL algorithm can segment COVID-19 lungs and has been utilized to detect the lesions in CT lung images on four separate occasions [45,49,50]. Since the PD dataset comprises a variety of motor symptoms, variables that have been observed in previous studies, AI models have also been developed to predict the disease [51–53]. Therefore, we believe that DL systems will be useful in the future for forecasting CVD/stroke risk classification in PD patients within the COVID-19 framework, and that developing a design approach will be beneficial in the near future.

The focus of this research was to design, develop, and validate the hypothesis, (i) CVD/stroke risk stratification of PD patients in the COVID-19 framework and (ii) understanding the non-linearity of PD combined with COVID-19 symptoms against the CVD/stroke gold standard; (iii) develop a DL-based lesion detection system and its quantification, which could then be used as a covariate in a machine learning framework; (iv) DL-based CVD/stroke risk stratification by combining office-based biomarkers (OBBMs), laboratory-based biomarkers (LBBMs), carotid ultrasound image-based (CUSIP), medicine usage (MedUSE), PD-based biomarkers, and CT-based COVID-19 lesion biomarkers.

2. Search Strategy

IEEE Xplore, Google Scholar, PubMed, and Science Direct were used to conduct an overall writing search. ‘CHD’, ‘PD patients and stroke risk stratification’, ‘neurodegenerative disease and symptoms’, ‘AI’, ‘machine learning, ‘deep learning, and ‘neurodegenerative disease’ were some of the key watchwords used in the study selection process. The research article was chosen for the studies that cover a wide range of topics, including CVD, and stroke risk stratification of PD patients in the COVID-19 framework using ML, DL, hybrid deep learning (HDL), and AI. The categorization of normal vs. PD-affected persons.
Figure 1 demonstrates the PRISMA model for the research article selection approach. Almost 204 research articles were identified from the listed sources, and 312 research studies were identified from additional sources during the identification phase. Articles that cross the research aim or have duplications were deleted from the total 412 studies. Articles were evaluated based on the viability of the selection strategy’s goal (336 studies). The papers that were not AI-based (n = 76) were ignored. Many of the articles did not meet domain requirements for reasons such as insufficient data, information, or poor presentation. As a result, the analysis was based on a total of 292 studies.

Figure 1. PRISMA model for selection of the studies, dealing with the effect of COVID-19 on PD for CVD and stroke risk stratification. (I: Included, E: Excluded).

Information from the data was considered for the PD with COVID-19 studies data, searches were: (i) name of the author, (ii) publication year of research article, (iii) objective of the research studies, (iv) effect of COVID-19 on PD, heart, and brain, (v) PD year (vi), PD with other comorbidities, (vii) diagnosis method, (viii) PD symptoms worsening factor due to COVID-19, and (ix) treatment of PD with COVID-19. The identified research studies were assessed using the unique and effective application of the AI, hybrid AI, PD with other comorbidities diagnosis techniques, and biomarker-based strategies for detecting CVD and stroke risk stratification of PD patients in the COVID-19 framework.

Figure 2a, studies related to PD with or without COVID-19. Figure 2b represents studies related to PD leading to stroke and heart disease with or without COVID-19. Every study was examined using a feasibility analysis and then cross-checked using scientific validation to ensure that it closely matched our objectives.
3. Pathophysiology of Lung and Parkinson’s Disease during COVID-19

The effect of COVID-19 on PD, the heart, and the brain is still unknown due to the limited literature, especially since we know that the lungs are badly affected by COVID-19 [54,55]. Note that PD patients already have several other comorbidities due to the older age group [6,16,56]. The symptoms related to PD with COVID-19 and other comorbidities introduce nonlinearity, causing challenges in the ML system for CVD/stroke risk stratification [16].

3.1. Acute Respiratory Distress Syndrome, Imaging, and Lung Lesions during COVID-19

The effect of coronavirus on lungs results in lower levels of ACE2 proliferating in the lung parenchyma cells. It leads to exacerbated neutrophil buildup, increased vascular permeability, and the production of diffuse alveolar and interstitial exudates in the lung. Pneumonia and acute respiratory distress syndrome (ARDS) are the results of this process [57]. As a result of an oxygen and carbon dioxide imbalance, ARDS is characterized by significant anomalies in blood gas composition that result in low blood oxygen levels [58]. This chronic hypoxia has been shown to cause myocardial ischemia and cardiac damage [59,60]. In the brain, hypoxia increases the rate of anaerobic metabolism in the mitochondrial brain cells [61], which results in increased cerebral vasodilation, edema, and decreased blood flow. There is a risk of cerebral ischemia and the development of acute cerebrovascular disorders, including acute ischemic stroke [61]. Figure 3 explains the pathway of ARDS formation.

To diagnose the abnormalities in the lung we need an imaging technique, and x-rays and computer tomography are the two medical imaging techniques that are most important in the detection and diagnosis of COVID-19 [47,62]. CT has demonstrated high sensitivity and repeatability. It also can detect various types of opacities, such as ground-glass opacity (GGO), consolidation, and other opacities [63,64], that are primarily seen [65,66]. The potential of ML systems to mimic traditionally established processes is outstanding, and this allows for faster illness identification and diagnosis [64]. The most significant flaw in such models is the features extracting method, which is arbitrary and, as a result, time-consuming [64]. It has recently been demonstrated that DL models can overcome this challenge [67,68]. In AI, deep learning is a branch that makes use of deep layers to provide self-driving feature extraction, classification, and segmentation of data input. The details on DL-based lesion segmentation and quantification will be explained in Section 5.
3.2. Vascular Damage Due to COVID-19

Vascular disorders create a threat to the heart and the brain [70]. The aortic arch, coronary artery, and carotid artery all have similar structures, this connection is extensively observed because the genetic composition of carotid and coronary arteries is similar (A to D) [71,72]. Even though they originate from a distinct main artery, these arteries run in opposite directions (Figure 4). Inflammatory cells such as polymorphonuclear cells, T-lymphocytes, histiocytes, monocytes, and mononuclear giant cells were found in all samples in the thrombus formation and all layers of vessels, along with endothelial proliferation and vascular endothelial, as well as collagen deposition and myofibroblastic proliferation to varying degrees. Endothelial damage can induce thrombosis in the arteries of the limbs and the aorta, as well as significant vascular events such as acute arterial hypoxia [73]. These cause LDL deposition and oxidation, plaque development, and arterial lumen constriction [74,75]. As a result, carotid artery disease may be used as a substitute biomarker for coronary artery disease in PD patients affected by COVID-19 [76]. COVID-19 is the cause of thrombosis in the arteries and veins and is also responsible for the unbalanced inflammatory state (cytokine storm) that also includes endothelial cells (1 to 12) [77].
3.3. Dopamine in Parkinson’s Disease with or without COVID-19

Dopamine acts as an intermediary between both the brain and the sensory systems that control and regulate movement [20]. The substantia nigra region of the brain loses nerve cells, causing PD. This part of the brain is responsible for producing dopamine, which is created by nerve cells [78]. This is a catalyst in the neuron neurodegeneration process because of the COVID-19 virus. Dopamine levels in the brain drop when these neuron cells die or are injured [79]. This shows that the brain area that governs movement is malfunctioning, resulting in delayed, unwanted, and uneven movements [80]. Nerve cell death is indeed a slow process. PD symptoms appear when roughly 80% of the substantia nigra cells in the brain are damaged [39,60].

Figure 5 represents neurons leading to dopamine gradually reducing the basal ganglia, resulting in motor and non-motor abnormalities, such as, (i) motor system rigidity [1], bradykinesia [52,81], postural instability [82], faced mask, and hypophonic speech [52], and (ii) non-motor symptoms including constipation [83], autonomic dysfunction [83], dementia [84], depression and sleep disorder [83], behavioral problems, as well as issues adapting to changes and stresses in their environment [1].

The cause of developing PD is still unknown, there is no specific reason why it happens in the aging population. Environmental factors may potentially increase a person’s likelihood of developing PD [1]. However, it is still unclear how specific inherited and hereditary factors contribute to a person’s risk of developing PD [82,83]. The defective genes are passed down from one generation to the next, and PD can run in families [85]. There have been indications that pesticides and herbicides used in agriculture, as well as industrial pollutants and traffic, could also be contributing factors to PD [86].

Figure 4. The inception of the left and right carotid arteries [69].
The most common consequences of PD on the heart are heart failure, abrupt death, and edema [87]. As a result, PD is associated with an increased risk of dementia and a higher than average rate of mortality and morbidity [19,88]. Patients with PD commonly experience the symptoms and signs of tremor, bradykinesia, rigidity, and uncontrollable movements [89–91]. All of the pathological variables that contribute to the development of clinical complexity in PD include inappropriate protein aggregation, oxidative stress, neuroinflammation, mitochondrial damage, and genetic anomalies [92,93].

### 4.1. The Relationship between Parkinson’s Disease and CVD

An artery’s epithelium becomes thickened or blocked as a result of plaque aggregation in the epithelium [97]. The autonomic nervous system (ANS) regulates a range of functions, including cardiovascular regulation through the heart and carotid artery baroreceptors (blood pressure valves) [98,99]. When baroreceptors detect a change in blood pressure, a signal is transmitted to specific brain locations, then the ANS transmits a signal to the heart, which regulates the heart rate and cardiac output [100,101]. Signals are also carried by the arteries, causing them to spasm and regulate blood pressure [102]. CVD and PD are influenced
by advanced age, diabetes, and gender. Dysregulation of the ANS can be caused by glucose metabolism, inflammation, cellular stress, or lipid metabolism \[103,104\]. The most common medical problem among older patients is stroke \[105\]. However, studies investigating the relationship between PD and stroke have shown conflicting results \[106,107\]. Strokes, such as cerebral ischemia, usually coincide with PD pathology according to postmortem investigations, and those clinically diagnosed with PD commonly have inflammation and fibrosis \[21\].

Patients with PD who are exposed to, (i) a cold environment, (ii) muscular activity in the early morning, (iii) standing positions, and (iv) over age, all have much higher sympathetic neuronal discharges, which leads to an increased myocardial oxygen requirement \[108,109\]. In the absence of a distinct clinical state, autonomic alterations cause homeostasis \[110,111\]. Thus, coronary artery stenosis demands more oxygen consumption and more coronary blood flow, but due to its shortage of blood flow and blood restriction, it results in ischemia and arrhythmias \[112,113\].

People with PD and a COVID-19 infection have a risk factor that causes myocardial infarction, as shown in Figure 6. The metabolic syndrome is always linked to a group of cardiovascular risk factors, such as abdominal obesity, high blood pressure (EBP), dyslipidemia, and low blood sugar. All of these factors are linked to CVD and a higher risk of death from CVD and other causes \[114\]. Table 1 covers several characteristics related to the relationship between PD and CVD without the COVID-19 effect.

![Figure 6. A risk factor in PD with COVID-19 patients responsible for myocardial infarction (Courtesy of AtheroPoint, Roseville, CA, USA).](image)

| SN | Citations | PS | ME | Relation * | Outcome | Treatment |
|----|-----------|----|----|------------|---------|----------|
| 1  | Huang et al. \[83\] (2015) | 156 | LBBM | Plasma cholesterol risk in PD | Total high cholesterol levels have been linked to a lower risk of developing Parkinson’s disease, but statin use has been linked to an increased risk. | Statins |
| 2  | Yan et al. \[72\] (2019) | 68  | LBBM | Carotid plaque in PD | As Parkinson’s disease advances, the thickness of carotid plaques rises. | NR |
| 3  | Potashkin et al. \[83\] (2020) | 47  | LBBM | CVD and PD | Both CV and PD share inflammation, insulin resistance, lipid metabolism, and oxidative stress. Moderate coffee consumption and physical activity reduce the risk of heart disease and PD. | NR |
| 4  | Park et al. \[35\] (2020) | NR  | Population-based cohort study | PD with risk of CVD | CVD is linked to PD. Patients with PD should be monitored for CVD. | NR |
Table 1. Cont.

| SN | Citations                        | PS | ME   | Relation * | Outcome                                                                 | Treatment                                                                 |
|----|----------------------------------|----|------|------------|--------------------------------------------------------------------------|----------------------------------------------------------------------------|
| 5  | De˘ girmenci et al. [64]          | NR | LBBM | Cardiac effect in PD | Cardiac problems are prevalent among Parkinson’s disease sufferers. | Levodopa, MOBI, COMT, anticholinergic drugs, deep brain simulations       |
| 6  | Scorza et al. [84] (2018)         | NR | LBBM | Cardiac abnormalities in PD | Cardiomyopathy, coronary heart disease, arrhythmias, conduction anomalies, and sudden cardiac arrest are among the symptoms of PD/PS. | NR                                                                       |
| 7  | Günaydın et al. [85] (2016)       | 65 | LBBM | CVD risk in PD under levodopa treatment | PD patients with L-dopa exhibited increased aortic stiffness and impaired diastolic performance. Homocysteine levels may influence diseases. | NR                                                                       |
| 8  | Fanciulli et al. [86] (2020)      | NR | LBBM | Orthostatic hypertension in PD | Orthostatic hypotension causes tachycardia, uncommon falls, disorientation, mental impairment, vision issues, fatigue, and painful shoulders, neck, or low back. They appear when the patient stands up and leave when the patient lies down. | Droxidopa, fludrocortisone, clonidine, transdermal nitroglycerin, nifedipine |
| 9  | Cuenca-Bermejo et al. [87] (2021) | NR | LBBM | Cardiac changes in PD | Cardiac anomalies have been observed in PD individuals who do not have sufficient sympathetic innervation in the heart. Hypotension after a meal is followed by supine hypertension; rising blood pressure variability, decreased heart rate and blood pressure, and chronotropic incompetence is all indications. Exercise may be beneficial in lowering the risk of cardiovascular disease in some people. High levels of blood cholesterol, tobacco smoking, and a high BMI have all been associated with the progression of PD. | NR                                                                       |
| 10 | Vikdahl et al. [88] (2015)        | 147| LBBM | CVD risk in PD |                                                                                       |                                                                            |

* SN: serial number, PS: patient size, ME: method of evaluation, Relation: effect of PD on stroke, NR: not reported, SSR: sympathetic skin response, HRV: heart rate variability, OI: orthostatic hypotension, LB: lab-based, MOBI: monoamine oxidase B inhibitors, COMT: catechol-O-methyl transferase inhibitors.

4.2. The Relationship between Parkinson’s Disease and Stroke without COVID-19

Stroke is one of the major causes of mortality in patients with PD [115,116], and this is often hemorrhagic stroke [20,117]. It is also the most common reason for long-term disability in PD patients [93,104]. Due to disturbance in the cerebral blood flow, there is an initiation of neuroinflammatory cascades that can impair the brain metabolism, which in turn leads to neuronal death [118–120]. Additionally, motor difficulties in PD patients lead to patient falls, resulting in traumatic brain injury. These are both major factors related to stroke risk [121].

Levodopa (also known as L-dopa) is the best treatment for PD [122]. Homocysteine levels have been reported to rise with the usage of L-dopa [78]. The pathogenic process of O-methylation of L-dopa to 3-O-methylidopa is linked to S-adenosyl methionine conversion to S-adenosyl-L-homocysteine and then homocysteine [123,124]. Patients with PD who take L-dopa and homocysteine have an increased risk of cardiovascular issues [125]. The most hazardous side effect of L-dopa is ventricular arrhythmia, although uncommon in a healthy heart, myocardial irritability and ischemia pose a serious threat to people who have them [126]. Patients with a history of cardiac abnormal activity should be approached with caution and monitored electrocardiographically [127]. Table 2 shows the link between
4.3. The Relationship between Parkinson’s Disease and COVID-19

The COVID-19 infection had quickly spread over the world since December 2019, resulting in a worldwide coronavirus pandemic in 2020 [7,129]. PD is a relatively common chronic illness among the elderly. Figure 7 shows the various motor and non-motor symptoms observed in PD patients with or without COVID-19. Fever, coughs, autonomic dysfunction, diarrhea, fatigue, and other symptoms have been recorded across several investigations as common COVID-19 clinical symptoms. COVID-19 also showed typical laboratory findings and irregularities on chest CT scans [130]. Figure 8 shows the symptoms of COVID-19 in PD patients. As seen in the graph, the cough is the most severe symptom, leading to upper respiratory tract infection, thus PD patients with COVID-19 have more severe lung lesions [4,131,132].
Several studies have shown the effect of COVID-19 on other comorbidities such as cardiovascular stroke [36,137], brain and heart injury [54], acute respiratory syndrome [50], pulmonary embolism [138], pneumonia [132], diabetes [8,139], prediction of coronary artery disease [140], thyroid cancer detection [44,141], and liver [33], prostate [142,143], and ovarian cancers [42,144] results in worsening the symptoms of the diseases and more complications in patients, resulting in a high mortality rate.

COVID-19 significantly exacerbated both motor and non-motor symptoms in PD, according to the current study, however, cognitive functioning was only minimally influenced [7]. Figure 9a represents various symptoms in PD patients. In terms of vulnerability, PD might be regarded as a high risk for infection, indicating the involvement of the respiratory system, which is frequently in the area of bradykinesia [130]. COVID-19-positive PD patients are more likely to be overweight, possess severe COPD, and not take vitamin D supplements than COVID-19-negative PD patients [145]. The negative correlation be-

### Table 2. Parkinson’s disease leading to stroke without COVID-19.

| SN | Citations | PS        | ME        | Relation *                        | Outcome                                                                 | TRE |
|----|-----------|-----------|-----------|-----------------------------------|------------------------------------------------------------------------|-----|
| 1  | Li et al. [112] (2018) | 63        | LBBM      | Stroke and CAD in PD              | When it comes to reducing the risk for heart disease, exercise may be useful in some cases. It has been discovered that having high amounts of blood cholesterol, smoking cigarettes, and having a high BMI are all connected with the development of PD. Both SSR and HRV tests are effective in detecting ANS failure in PD patients, not only in the later stages but also in the early stages. Patients with PD may benefit from utilizing these tests to rule out autonomic dysfunction. | NR  |
| 2  | Studer et al. [133] (2017) | 73        | LBBM      | Heart-rate variability and skin resonance in PD | Since cerebrovascular and neurodegenerative diseases coexist, cerebral infarction is linked to PD. However, even though levodopa raises homocysteine levels, it is the most effective and required symptomatic treatment for many PD patients. | NR  |
| 3  | Liu et al. [134] (2014) | 32        | Self-reporting | Stroke in PD | Homocysteine levels that are too high in people who have PD may make them more likely to have a stroke. There has been a link between high levels of homocysteine and a higher likelihood of stroke and heart disease. Vascular disease and dementia, as well as a rise in homocysteine levels in the blood after taking levodopa, are some of the side effects. | NR  |
| 4  | Becker et al. [20] (2009) | NR        | LBBM      | Risk of stroke in PD              | Patients with neurological problems can benefit from exercise training by feeling less physically and mentally worn out all the time. People with PD who engage in cardiovascular activity report less fatigue as a result of their efforts. | NR  |
| 5  | Levine et al. [105] (2009) | NR        | LBBM      | Traumatic brain injury in PD       | Patients with chronic neurological illnesses are more likely than the general population to experience debilitating depressive symptoms. It is unclear what causes them, but they may be multifactorial in some cases. | NR  |
| 6  | Rickards [135] (2005) | NR        | NR        | Stroke in PD                       | Findings were not directly compared with those of prior investigations of stroke-related mortality and morbidity in the PD group following postmortem examination. | NR  |
| 7  | Mastaglia et al. [136] (2002) | 100       | Self-reporting | Prevalence of stroke in PD | | NR  |

* SN: serial number, PS: patient size, ME: method of evaluation, Relation: effect of PD on stroke, NR: not reported, SSR: sympathetic skin response, HRV: heart rate variability, OH: orthostatic hypotension, LB: lab-based.
between COVID-19 and vitamin D supports the hypothesis that hypovitaminosis D may be a contributing factor to COVID-19 susceptibility [146]. In other groups, obesity and respiratory disease are well-documented risk factors for heart disease and stroke [147], and the negative relation with vitamin D continues to support the suspicion that iodine deficiency may contribute to COVID-19 susceptibility. Vitamin D insufficiency is frequently found in people with PD [148], and some researchers have suggested that vitamin D treatment might protect people against both COVID-19 and PD [149]. The association between PD and COVID-19 is depicted in Table 3. The majority of research makes observations about the size of the PD/non-PD dataset, its demographics, and aligned comorbidities. PD is always associated with comorbidities along with high age [130,150]. Figure 9b shows the risk factors of PD and COVID-19 with comorbidities [6,129].

Figure 9. (a) The symptoms in patients with joint PD and COVID-19. (b) Risk Factors of PD and COVID-19 with comorbidities.

4.4. Effect of Comorbidities on Parkinson’s Disease

This section explains the role of various comorbidities that trigger the motor and non-motor symptoms of the PD patient, and whether the patient falls under the high-risk category. Dementia develops when neurons die, causing chemical changes in the brain [11,12]. In the literature, PD is always associated with comorbidities along with high age. The long duration of PD falls under the high-risk categories [19,24,130,134]. In terms of vulnerability, PD might be regarded as a high-risk condition for infection, indicating the involvement of the respiratory system, which is frequently in the area of bradykinesia [130].

Depression is a mental illness that can decrease a human’s capacity to carry out everyday tasks, and anxiety affects around half of the people with PD [151]. This is regarded to be separate from being depressed as a result of their illness. Depression, like uncontrollable shaking, is thought to be a sign of PD. Both are brought on by changes in brain chemistry [9,10].

Persons with PD have a higher chance of having TMD than people without PD [152]. In most cases, the disc inside the jaw area moves out of position. The muscles in the joint are essentially ‘pinched’ by the slipped disc, causing them to transmit odd signals to the brain, resulting in tics or shaking [13,153]. As the dentures wear out or are removed, the jaw bone collapses into the jaw joint, which is common in older adults having PD [154,155].

People with PD have trouble passing urine since their bladders will not contract as they should. Furthermore, their sphincter muscles don’t allow urine to pass out [156]. This is due to low levels of dopamine affecting the bladder’s movement effectiveness, resulting in a residual quantity of urine remaining in the bladder [157]. This lowers the bladder’s total capacity and makes it feel as if it has to be emptied often. Unfortunately, if the bladder is not emptied, there is an increased chance of CKD [156,158]. The main cause of that disease is neurodegeneration, which damages the brain cells. The symptoms of PD and Alzheimer’s disease are dementia, anxiety, fear, and sleeping problems [151]. Neurological
diseases can cause hallucinations and delusions, which are psychiatric symptoms [159]. COVID-19 considerably increases motor and non-motor symptoms in PD.

Osteoporosis and osteopenia are common among PD patients, with women experiencing the condition at a higher rate than men [160]. Decreasing movement in PD appears to be the primary cause of decreased bone density, a process similar to that seen in other neurological illnesses [161]. Figure 10 shows hypertension (33.17%), CPD (6.98%), paralysis (5.53%), cerebrovascular disease (42.53%), and diabetes (10.60%) were the most common comorbidities among PD patients [162].

![Figure 10. Effect of comorbidities on PD with or without COVID-19 [162].](image)

Table 3. Studies showing the effect of COVID-19 on PD.

| SN | Author                  | Year | Demography | Age | Sex | Type                  | Data Size | Non-PD | PD | PD w/s COVID | PD Years | Gold Standard                                  |
|----|-------------------------|------|------------|-----|-----|-----------------------|-----------|--------|----|---------------|-----------|-----------------------------------------------|
| 1  | Antonini et al. [56]    | 2020 | European   | 68  | MF  | PD with COVID         | 10        | 0      | 10 | 10            | 20        | PD + COVID-19 + Respiratory dysfunctions     |
| 2  | Baschi et al. [7]       | 2020 | European   | 60  | MF  | PD with COVID         | 34        | 0      | 34 | 34            | 6         | PD + COVID-19 + Pneumonia                   |
| 3  | Brown et al. [163]      | 2020 | European   | 70  | MF  | PD with COVID         | 102       | 40     | 62 | 51            | 4         | PD + COVID-19 + Respiratory dysfunctions     |
| 4  | Cella et al. [2]        | 2020 | European   | 65  | MF  | PD with COVID         | 141       | 0      | 12 | 12            | 4         | PD + COVID-19 + Respiratory dysfunctions     |
| 5  | Starmbi et al. [129]    | 2021 | European   | 65  | MF  | PD with COVID         | 105       | 0      | 32 | 32            | 4         | PD + COVID-19 + Pneumonia                   |
| 6  | Helmich et al. [6]      | 2020 | European   | NR  | NR  | PD with Covid         | NR        | NR     | NR | NR            | NR        | PD + COVID-19 + Respiratory dysfunctions     |
| 7  | Khoshnood et al. [5]    | 2021 | European   | NR  | NR  | PD with COVID         | NR        | NR     | NR | NR            | NR        | PD + COVID-19 + Pneumonia                   |
4.5. The Relationship between Combined Parkinson’s Disease and COVID-19 on CVD/Stroke

PD patients with underlying diseases like CVD, diabetes mellitus, and hypertension are more vulnerable due to COVID-19 as it increases cardiac events [164]. Meanwhile, in PD the automatic control of the cardiovascular system is disrupted for two primary reasons. First and foremost, Lewy bodies are usually seen in the brain regions that govern the system, and these regions have also suffered from neurodegeneration [133]. Furthermore, inclusions resembling Lewy bodies and neurodegenerative diseases have a direct impact on the ANS [165]. Therefore in some cases, an attempt to raise blood pressure by the carotid artery and the heart’s baroreceptors is unsuccessful because the signals are not received [15]. As the ANS malfunctions excessively, this results in neurogenic orthostatic hypotension (nOH) or a fall in blood pressure when the PD patient walks [14,15].

Many reports regarding hospitalized patients have indicated that 12% to 26% of them had suffered heart damage. The cytokines generated during the COVID-19 infection may affect the patients’ intracellular coronary arteries. In individuals with COVID-19-affected lungs, cardiovascular illnesses have a significant impact on the ARDS [166]. These processes that lead to SARS-CoV-2 might cause a susceptible plaque to become complex and burst [55].

ACE2 receptors are highly expressed in dopaminergic neurons and are lowered in PD due to the degenerative changes [167]. Central nervous system penetration caused by the acute respiratory syndrome, SARS-CoV-2, may cause considerable harm, worsen illnesses, and increase the need for dopamine hormone treatment [168]. In many infected patients, the COVID-19 virus’s capacity to enter the brain through the nasal cavity causes anosmia/hyposmia and ageusia, addressing the variations which closely mirror one of the most notable premotor symptoms of PD [2], neurodegeneration as SARS-CoV-2 promotes the accumulation of alpha-syncline (aSyn), the major protein component of Lewy bodies in the brain [163,169,170]. Pathways impacted by a viral infection, like proteostasis, are important in maintaining dynamic equilibrium and activating stress response mechanisms, which appear to be targeted in neurodegenerative processes [163].

The biochemical link between PD with COVID-19 and CVD is seen in Figure 11. It has been observed that as the infection of SARS-CoV-2 takes place through the central nervous system (CNS) and in the basal ganglia region of the brain, it triggers ACE-2 enzymes, which results in the adaptive immune response that leads to autophagy deficiency, endoplasmic reticulum stress, and loss of proteostasis [56,130].

| SN | Author | Year | Demographics | Age | Sex | Type | Data Size | Non-PD | PD | PD w/s COVID | PD Years | Gold Standard |
|----|--------|------|--------------|-----|-----|------|----------|--------|----|-------------|----------|---------------|
| 8  | Lau et al. [16] (2021) | 2021 | European | NR | NR | PD with COVID | NR | NR | NR | NR | 12 | PD + COVID-19 + Respiratory dysfunctions |
| 9  | Sulzer et al. [4] (2021) | 2021 | NR | NR | NR | PD with COVID | NR | NR | NR | NR | NR | PD + COVID-19 + Respiratory dysfunctions |
| 10 | Tsivgoulis et al. [131] (2021) | 2021 | NR | NR | NR | PD with COVID | NR | NR | NR | NR | 6 | PD + COVID-19 + Pneumonia |
| 11 | Sorbera et al. [130] (2021) | 2021 | European | 65 | MF | PD with COVID | 18 | 5 | 13 | 9 | 3 | PD + COVID-19 + Pneumonia |
Oxidative stress has been proven in several studies to be the most essential contributor to the development of PD that leads to CVD [79,171]. Mitochondrial dysfunction is promoted by excessive generation of reactive oxygen species (ROS) [172]. Nevertheless, as Yu et al. [173] and Bennett et al. [174] showed, it also stimulates the progression of atherosclerosis through multiple methods. Furthermore, as seen in Figure 9, mitochondrial dysfunction causes PD and cardiac injury via four separate pathways.

The substantia nigra’s selective loss of dopaminergic neurons involves oxidative stress as a critical stage [175] and is explained by path (A) of Figure 11. Resting tremors, stiffness, and balance problems are the three main signs of PD [176]. Oxidative stress damages beta cells in the pancreas and promotes the growth of oxidative lipoprotein oxidation (OxLDL) in route (B). This causes endothelial dysfunction in arteries [177]. Inhibited endothelial cell intercellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM) levels increase the stickiness [178]. These reduce nitric oxide (NO) levels, which support the development of the atherosclerotic plaque [179]. Furthermore, route (C) and (D) depict the link between mitochondrial dysfunction leading to infections and generating the cytokine storm that leads to plaque disturbance, which is a substantial joint risk factor for PD and cardiovascular disease [180,181]. Excess ROS and mitochondrial impairment are both

Figure 11. COVID-19 virus pathways leading to stroke and CVD in PD patients (Courtesy of AtheroPoint, Roseville, CA, USA).
involved in the pathophysiology of PD and CVD [182]. The US is the most widespread technique used, it is simple to use, has a high resolution, is cost-effective, and is a user-friendly image collection modality for plaque detection [183]. As a result, it has a broad use for regular atherosclerotic plaque monitoring and CVD risk analysis [184,185].

5. Deep Learning for CVD/Stroke Risk Assessment in PD Patients with COVID-19

To stratify an early CVD/stroke risk in PD patients embraced by the COVID-19 framework, AI is the most promising and optimal solution due to its ability to handle non-linearity during the training process [186]. The class of AI was first dominated by the ML systems consisting of a variety of applications, including diabetes [139,187,188], neonatology [189], genetics [190,191], coronary artery disease risk stratification [140,192], classification of carotid plaques [193], and cancer risk stratification in organs such as the thyroid [39,194,195], breast [196], ovary [142,197], and prostate [144,198], to name a few. These methods have generic drawbacks such as ad hoc feature extraction during the training/prediction design.

DL has been shown to have penetrated all walks of life and more recently into healthcare imaging [199,200]. A deep neural network (DNN) is a class of DL that mimics the human brain [32]. DL uses the power of convolution, max pooling, and different kinds of channels such as attention maps including spatial and temporal, to automate the feature extraction, classification, and segmentation paradigms [201,202]. Many studies have already described the use of AI in the diagnosis and prediction of PD [137,157,203–205] or prediction of early COVID-19 lesions [49,54,129,206]. Further, DL has also played an important role in the diagnosis of COVID-19 in the presence of comorbidities, such as diabetes [36], CVD [38,184,207], rheumatoid arthritis [208], and pneumonia [150]. When such comorbidities are present in the patients besides PD and COVID-19, it severely affects the non-linear dynamics. As a result, the role of DL becomes even more important and prominent in CVD/stroke risk stratification [209]. We, therefore, need better biomarkers that can measure COVID-19 severity. One such biomarker is the COVID-19 lesion size. Section 5.1 shows the role of DL for COVID-19 CT lung lesion segmentation and quantification, while Section 5.2 shows the role of DL for CVD/stroke risk stratification in PD patients affected by COVID-19.

5.1. Deep Learning for COVID-19 Lesion Segmentation and Its Quantification in CT

The power of DL for COVID-19 lesion detection has been shown in previous studies using different imaging modalities [17,210–213]. In fact, the use of DL has been investigated for lesion detection in several applications, such as in, (i) common carotid artery [208,214], (ii) coronary artery [140,213], (iii) brain tumor [212], (iv) skin cancers [211,215], and (v) CT-based pulmonary imaging [132]. The pulmonary lesions during COVID-19 are caused by the single-stranded RNA virus SARS-CoV-2, which infects the human cells induced by angiotensin-converting enzyme II (ACE2), which in turn leads to interstitial damage [216]. When it comes to the lesion, the stiffness in the lung muscle can be categorized as another lesion due to PD, known as bradykinesia [52,81], where the lung muscles become weaker.

Here, we focus on CT-based lung lesion segmentation and its quantification, which acts as a covariate (or feature) during the DL paradigm. In DL, manual delineations of CT lung lesions are challenging and are also vital for the design of offline DL training models. Figures 12 and 13 illustrate the highlighted COVID-19 lesions in CT lungs using manual delineation by experienced tracer 1 and 2, respectively. This is shown in the red color lesion as an overlay image with a grayscale CT image in the background. When it comes to COVID-19 lung lesion detection and quantification in CT, Suri et al. [217,218] have demonstrated the usage of hybrid DL (HDL) models vs. solo DL (SDL) models, exhibiting its superiority for lung lesion segmentation in CT scans. One of the most important aspects of DL is the optimization of hyperparameters during training to obtain the best performance of the DL system. It thus requires optimizing, (i) learning rate, (ii) number
of epochs, (iii) batch size, and (iv) batch normalization, and (v) adding dropout layers to prevent overfitting and obtain generalization. Further, to achieve the best DL design, one must use several sources of biomarkers with a different set of data sources in a large amount in a big data framework, ensuring a multiresolution framework for faster execution time [202]. Transfer learning can also be used in CT lesion segmentation for transferring the knowledge between models, so-called pretrained models, ensuring higher speed [150,219]. Table 4 shows a variety of pretrained DL models such as DenseNet 201, ResNet50 V2, MobileNet, and VGG-16. SegNet and UNet models are stronger than the CNN models. The ResNet50 V2 model has higher accuracy compared with the 3-layer CNN and VGG-16 networks.

Figure 12. Manual lesion delineation overlays (red) from tracer 1 on raw CT lung images (Courtesy of AtheroPoint™, Roseville, CA, USA permission granted).
Figure 13. Manual lesion delineation overlays (red) from tracer 2 on raw CT lung images (Courtesy of AtheroPoint™, Roseville, CA, USA permission granted).

Table 4. Pretrained models for COVID-19.

| SN | Authors and Citations | Total CT Scan Samples | Pretrained Model | Accuracy (%) |
|----|-----------------------|-----------------------|------------------|--------------|
|    |                       | Positive COVID-19 | Negative COVID-19 |              |
| 1  | Halder et al. [206] (2021) | 1252 | 1229 | DenseNet 201 | 97.00 |
|    |                       |          |                  | ResNet50 V2 | 96.00 |
|    |                       |          |                  | Mobile Net | 95.00 |
|    |                       |          |                  | VGG-16    | 94.00 |
|    |                       |          |                  | VGG-16    | 87.68 |
|    |                       |          |                  | 3-layer CNN | 56.16 |
| 2  | Kumari et al. [189] (2020) | 921  | 921   | Pretrained Model | Accuracy (%) |
| 3  | Mishra et al. [211] (2021) | 360  | 397   | Deep CNN | 86.00 |
| 4  | Saood et al. [175] (2021)  | 287  | 314   | SegNet  | 95.00 |
|    |                       |          |                  | Unet      | 92.00 |
5.2. Deep Learning for CVD/Stroke Risk Assessment for Joint PD and COVID-19 Patients

DL is a strong framework because it has the ability to derive the automated features using the inherent knowledge base and further offers a superior training paradigm where the non-linearity between covariates and the gold standard is dynamically adjusted. One such typical system for DL design is shown in Figure 14. This architecture consists of: (a) a training model design utilizing the risk variables taken from six sources such as office-based biomarkers (OBBM), laboratory-based biomarkers (LBBM), carotid image-based phenotypes (CUSIP), medication consumption (MedUSE), PD, and COVID-19, derived from the training dataset, and (b) risk prediction labels as part of the gold standard which are either heart failure (cardiovascular events) or stroke (cerebrovascular events) [220]. Such a training system can be non-linearly adjusted and has been shown recently in the context of cardiovascular risk stratification [38,185,207,221,222]. The image-based phenotypes derived from the carotid ultrasound scans are considered CUSIP [67] such as carotid intima-media thickness (cIMT, ave., max., min), intima-media thickness variability (IMTV), and total plaque area (TPA). The choice of carotid artery non-invasive imaging [48] with noise-reduction capability is preferred for economic reasons [44,223]. The carotid wall segmentation aids in the detection of plaque build-up [224,225].

![Figure 14. Deep learning model to predict the severity of CVD/stroke in PD with COVID-19 framework (Courtesy of AtheroPoint™, Roseville, CA, USA).](image-url)
The DL-based detection of PD can be conducted by using symptoms of PD as an input parameter for the algorithm. There are numerous investigations that link changes in voice [226] to a diagnosis of PD. Also, tremor [1], EEG [227], and sketch [228] biomarker data are important factors in determining if the patient has PD or not. Table 5 lists AI studies showing PD detection without COVID-19. Performance parameters of 12 studies aligned with the type of input and AI architectures. The AI-based detection of PD can be achieved by using symptoms as an input parameter for the algorithm. The majority of the studies explain voice as an input parameter for the diagnosis of PD.

Table 5. AI techniques and their performance for PD detection without COVID-19.

| Attributes (Left to Right) | Citations | C1 IP | C2 AI | C3 CLS | C4 ACC | C5 SEN | C6 SPEC | C7 AUC | C8 MCC | C9 F1 |
|---------------------------|-----------|-------|-------|-------|-------|-------|--------|--------|--------|-------|
| Hoq et al. [229] (2021)   | Voice     | HDL   | SVM   | 94.0  | NR    | NR    | NR     | 0.71   | 0.91   |
| Kamble et al. [230] (2021)| Voice     | HDL   | SVM   | 96.0  | NR    | NR    | NR     | 0.87   | NR     |
| Alzubaidi et al. [231] (2021)| Tremor  | HDL   | DT    | 87.9  | NR    | NR    | NR     | 89.34  | 1.17   |
| Khedr et al. [232] (2021) | Voice     | ML    | SVM   | 95.8  | 90.24 | 92.3  | NR     | 92.03  | 96.00  |
| Mei et al. [53] (2021)    | Voice     | ML    | KNN   | 83.07 | NR    | NR    | NR     | 0.91   | NR     |
| Singamaneni et al. [1] (2021)| Voice   | ML    | SVM   | 94.86 | NR    | NR    | NR     | NR     | NR     |
| Jayachandran et al. [233] (2020)| Voice | ML    | NB    | 78.34 | NR    | NR    | NR     | NR     | NR     |
| Anitha et al. [234] (2020)| Voice     | ML    | SVM   | 90.21 | 1.8   | 4.39  | 2.49   | NR     | 1.17   |
| Maitm et al. [235] (2020) | EEG       | ML    | LR    | 62.99 | 0.9067| 0.981 | NR     | NR     | NR     |
| Poorjam et al. [236] (2019)| Voice    | HDL   | SVM   | 96.00 | NR    | NR    | NR     | NR     | NR     |
| Aseer et al. [237] (2019) | Voice     | HDL   | SVM   | 98.28 | NR    | NR    | NR     | NR     | NR     |
| Noghub et al. [238] (2019) | EEG       | SDL   | DT    | 97.38 | NR    | NR    | NR     | NR     | NR     |
| Wang et al. [234] (2017)  | BM        | HDL   | KNN   | 96.12 | NR    | NR    | NR     | NR     | NR     |

AUC: Accuracy, SEN: Sensitivity, IP: Input parameter, AI: Artificial intelligence model, CLS: Classifier, SPEC: Specificity, MCC: Matthew’s correlation coefficient, NPV: Net present value, F1: Dice similarity coefficient; HW: Handwriting, BM: Biomarker, NR: Not reported, HDL: Hybrid deep learning, DL: Deep learning, EEG: Electroencephalogram.

5.3. Deep Learning LSTM Architecture

Long short-term memory (LSTM) is one of the DL algorithms that can be used to assess the risk of CVD/stroke (Figure 15). The ability to analyze several types of datapoints, such as a single observation, is the fundamental feature of LSTM. This architecture consists of four main components: cells, update gates, output gates, and forget gates (Figure 15). A cell is the central component of the design. The values are stored in the cell during random intervals, and the three gates control the flow of information or features into and out of the cell [238]. LSTM is composed of four dense layers that are fully coupled and stacked on top of one another [239,240]. LSTM performs better when it comes to formulating long-term interconnections in data [241].
5.4. The Comparative Analysis of AI Systems with a Different Set of Input Covariates

In previous sections, we demonstrated how patients having PD with COVID-19 increase CVD/stroke-related complications. We propose in Table 6 several AI-based studies for the CVD/stroke risk stratification of PD patients in the COVID-19 framework. The main ingredient of this table is the use of input covariates for the AI design for CVD/stroke risk stratification. Due to the addition of a large number of covariates, the non-linear dynamics increases and therefore affects the AI models during training and prediction, affecting the accuracy. We thus need robust DL-based systems for CVD/stroke risk prediction and stratification. There are six types of covariates that are used for the design of the AI models, and we call them six types of AI clusters labeled as: (i) OBBM, (ii) LBBM, (iii) CUSIP, (iv) MedUSE, (v) PD, and (vi) COVID-19. Note that the gold standard in all AI design solutions while considering these covariates are patients who had a myocardial infarction, coronary artery syndrome, coronary artery stenosis, or stroke. These clusters are discussed below:

(i) AI systems that use office-based biomarkers as input covariate
All the studies in Table 6 use OBBM as an input covariate, and this consists of attributes such as height, weight, BMI, gender, ethnicity, smoking status, hypertension, and cholesterol levels. An example of OBBM use is Kakadiaris et al. [243], where the authors proposed an ML-based risk calculator for a multiethnic, community-based population of men and women examined for incidental atherosclerotic CVD. The authors employed ACC/AHA risk assessment variables and had an ML accuracy of 86%.

Reva et al. [244] described the first AI-based algorithm for CVD risk assessment capable of reliably monitoring the collateral flow in androgen insensitivity syndrome (AIS) patients. This is an automated technique that reduces bias and streamlines the clinical process, which helps in determining reperfusion-eligible patients. Collateral circulation is connected to a better functional outcome in acute ischemic stroke patients with major arterial occlusion. Due to complex neuro-vasculature, evaluating collateral flow can be difficult and time-consuming. The authors adopted SVM and RF-based ML algorithms for the classification of AIS patients vs. controls. The model used 300 patient data and reported an accuracy of 87%.

(ii) AI systems that use laboratory-based biomarkers as input covariate

Biomarkers are chemicals released into the blood by a damaged or stressed heart. These indicators are used to diagnose acute coronary syndrome and myocardial ischemia. Cardiovascular biomarker tests can also be used to assess a patient’s risk of developing CVD or heart ischemia. There are various LBBM related to the heart such as low-density lipoprotein, high-density lipoprotein, myoglobin, creatine kinase, troponin, atrial natriuretic peptide, etc. For example, the study by the Unnikrishnan et al. [245] described a method for assessing CVD risk associated with health indicators, many of which are derived from the Framingham risk score. These approaches, however, have major limitations as a result of their low sensitivity and specificity. The study reported a cohort size of 3665 patients for studying the effect of model training on the local database, computed the Framingham score, and established the linear regression analysis. The study presented an AI model and reported an accuracy of 83%.

(iii) AI systems that use carotid ultrasound image phenotype as a covariate

In order to perform a comprehensive risk assessment, we must be able to automatically and precisely quantify CUSIP [246], which consists of carotid intima-media thickness, average, maximum, and minimum (cIMTave, cIMTmax, and cIMTmin), carotid intima-media thickness variability (cIMTV), morphological total plaque area (mTPA), geometric total plaque area (gTPA), lumen diameter (LD), and inter-adventitia [247]. We need a risk assessment system that can determine the severity of coronary artery disease in patients who present to the emergency department. All emergency department examinations discovered an increase in cardiovascular disease, which was found to be associated with an increase in phenotypes such as cIMT, gTPA, mTPA, and CRS. This CUSIP is then used as a covariate in the ML algorithm to further improve the results (Figure 16) [246]. Suri et al. [248] explained the risk of CVD/stroke in PD patients by using carotid artery imaging, since it was low-cost, non-invasive imaging for the screening. PD patients will benefit from the adoption of this low-cost B-mode ultrasonography since it will allow for the characterization of plaque tissue. This will provide a critical additional understanding of CVD/stroke risk stratification in PD patients.

(iv) AI systems that use Parkinson’s disease symptoms as input covariate

The PD input covariates are voice, gait, sketch pattern, and abnormalities in EEG. The motor and non-motor symptoms result in a better understanding of whether patients have PD or not. Another study by Park et al. [249] used EEG as an input to predict the stroke severity in the PD patients. It implemented the SVM algorithm for the classification. The cohort size consisted of only 16 patients, which was relatively small. The study reported an accuracy of 88%.
Figure 16. (a) Carotid artery disease is being investigated as a potential surrogate marker for coronary artery disease. (b) Imaging device where the carotid artery is being scanned with the linear ultrasound probe. The middle panel shows the B-mode carotid longitudinal US scan and IVUS-based artery cross-sectional scan [250].

(v) AI systems that use COVID-19 as input covariate

The DL algorithm is used by the vast majority of AI-based systems for COVID-19 identification and categorization. To improve the amount of COVID-19 data available for training, some researchers have adopted data augmentation techniques. Scientists must modify the number of convolution layers in accordance with their intuition when working with this hyperparameter. However, for COVID-19, DL-focused AI systems must be adjusted based on the link between enhancement, the number of convolution layers, and classification accuracy. The study by Suri et al. [54] presented an ML model that can be used to predict the severity of CVD/stroke in COVID-19 patients. In these review studies, the authors have validated their findings that COVID-19 causes damage to the brain and heart through four distinct pathways (i.e., neuronal, hypoxia, RAAS, and immunological). The degree of risk linked with a patient’s symptoms, and invasive imaging techniques, whether portable or non-portable, must be performed with the utmost care. Even though medical imaging [251] can considerably improve a patient’s odds of survival, the shortage of qualified radiologists prevents it from being widely utilized. Furthermore, a study by Zimmerman et al. [252] explained the significance of comorbidity appears to be associated with adverse outcomes in COVID-19 patients. The uses of AI, particularly ML, have the potential to utilize data-rich platforms and alter methodologies in the diagnosis, risk stratification, prevention, and treatment of CVD. The patient size used was 32. The LDA method was used for extracting features. The CNN algorithm was used for classification purposes and the study reported an accuracy of 87%.

Another study by Handy et al. [253] explained the mortality rate prediction of CVD/stroke in COVID-19 patients. The study explained the atrial fibrillation parameter for the benchmarking of the stroke risk prediction method. The DL-based LSTM algorithm was used for the analysis purpose. The study reported an accuracy of 84%. Another study by Bergamaschi et al. [254] determined the significance of serial ECG abnormalities in hospitalized individuals with COVID-19. These findings showed the role of ECG abnormalities were detected at admission and even more, were observed at the 7-day ECG, which could assist doctors in stratifying the risk of significant adverse events in COVID-19. The severity of the SARS-coronavirus-2 infection was found to be linked to changes in the ECG. To our knowledge, no AI study has been able to give clear and useful information related to the CVD/stroke risk stratification of PD patients in the COVID-19 paradigm.

Hence, we hypothesize that DL models are capable of performing a specific task, such as automated disease diagnosis, with greater precision and efficiency than ML models and
act as a second level of confirmation for the diagnosis [255]. Models trained with deep learning can be applied to a wide variety of problems, including image-based quantification, improvements to image acquisition, and differential diagnosis.

Table 6 shows the comparison between the proposed ML/AI algorithms and similar techniques for CVD/stroke risk prediction. There were published techniques available in the literature. There are other AI-based CVD/stroke and non-AI-based CVD/stroke risk stratification methods that use carotid-based biomarkers with conventional risk factors. AI-based methods have used ML techniques with conventional biomarkers or a combination of conventional biomarkers with carotid-based image phenotypes [38,184,185,207,209,221,256,257]. The main concept behind these studies was to add the covariates such as cIMT (average, max., min), IMTV, and TPA along with conventional biomarkers such as A1c, LDL, HDL, triglycerides, SBP, DBP, BMI, and age. The system designed used standardized classifiers for training when using the cross-validation approaches. For prediction system design, the test data was adapted where the training model transformed the test features. These methods are mainly called the class of AtheroEdge™ 3.0 system designs (AtheroPoint, Roseville, CA, USA). In the non-AI-based methods for CVD/stroke the risk was determined by computing the digital total of all the normalized risk values for the image-based biomarkers and then compartmentalized into different risk classes such as no-risk, low-risk, low-moderate risk, high-moderate risk, low-of-high risk, and high-of-high risk. This was computed using the AtheroEdge™ 2.0 system (AtheroPoint, Roseville, CA, USA) [36,220,221,258–265]. Image-based biomarkers, such as TPA, have shown to have a strong link with eGFR [266], and thus AI-based solution have adapted the usage of TPA in the modeling process. AtheroEdge systems were designed to keep both AI-based and non-AI-based methods at a low cost [267]. Note that the importance of the automated biomarker guidelines were recently revisited for CVD/stroke risk stratification [265], thus the above AI-based and non-AI-based methods are powerful solutions for CVD/stroke risk assessment.

Table 6. Comparative analysis of AI-based studies with CVD/stroke risk stratification of PD patients in the COVID-19 framework.

| SN | Citations          | Year | Input Covariates | GT | PS | AI | FE | CLS | ACC % | AUC |
|----|--------------------|------|------------------|----|----|----|----|-----|-------|------|
| 1  | Yan et. al. [268]  | 2019 | ✓ X X X X CVD    | NA | NA | NA | NA | NA  | 88.00 | NR   |
| 2  | Park et al. [249]  | 2017 | ✓ ✓ X X ✓ Stroke | 18 | ML | RF | SVM | 88.00| NR   |
| 3  | Suri et al. [248]  | 2022 | ✓ ✓ ✓ ✓ X CVD/stroke | NR | ML | NR | NR  | NR   | 88.00| NR   |
| 4  | Zimmerman et al. [252] | 2020 | ✓ ✓ X X X CVD | 32 | DL | LDA | CNN | 87.23| NR   |
| 5  | Aljameel et al. [269] | 2021 | ✓ ✓ X X X CVD/stroke | 287 | ML | KNN | SVM | 95.00| 0/99 |
| 6  | Suri et al. [54]   | 2020 | ✓ ✓ ✓ ✓ X CVD/stroke | NR | ML/I | NR | NR | NR   | 88.00| NR   |
| 7  | Handy et al. [253] | 2021 | ✓ ✓ ✓ X X CVD/stroke | NR | ML/I | LSTM | SVM | 84.00| NR   |
| 8  | Unnikrishnan et al. [255] | 2016 | ✓ ✓ X X X CVD | 3654 | ML | LR | SVM | 83.00| NR   |
| 9  | Mouridsen et al. [270] | 2020 | ✓ ✓ X X X Stroke, MRI | 16 | DL | NR | KNN | 74.00| 0.74|
| 10 | Bergamaschi et al. [254] | 2021 | ✓ ✓ X X X CVD | 237 | NA | NA | NA | NA   | 88.00| NR   |
Table 6. Cont.

| SN  | Citations          | Year | OBBM | LBBM | CUSIP  | MedUSE | PD | COV     | GT       | PS | AI | FE | CLS | ACC % | AUC |
|-----|--------------------|------|------|------|--------|--------|----|---------|----------|----|----|----|-----|-------|-----|
| 11  | Reva et al. [244]  | 2021 | ✓    | ✓    | ×     | ×      | ×  | ×       | Stroke, CT | 200| ML | NB | DT, RF | 85.32 | NR  |
| 12  | Kakadiaris et al. [243] | 2022 | ✓    | ✓    | ×     | ×      | ×  | ×       | CVD       | 6459| ML | DT, RF | SVM | 86.00 | 0.92 |
| 13  | Proposed study     | 2022 | ✓    | ✓    | ✓    | ×      | ✓  | ✓       | CVD/stroke | NA | NA | NA | NA  | NA   | NA  |

IC: Input covariate, COV: COVID-19, PD: Parkinson’s disease, CVD: Cardiovascular disease, AI: Artificial Intelligence, OBBM: Office-based, LBBM: Laboratory-based, CUSIP: Carotid ultrasound image phenotype, MedUse: Medication, GT: Ground truth, PS: Patient size, FE: Feature extraction, CLS: Type of classifier, ACC: Accuracy, AUC: Area under the curve, NA: Not applicable, NR: Not reported, ✓: Yes, ×: No.

5.5. Implementation and Maintenance of AI-Based CVD Risk Stratification System

Cardiovascular disease (CVD) is the most prominent cause of global mortality and morbidity. Annually, ~17.9 million people die due to CVD, which accounts for 31% of the overall deaths worldwide. Atherosclerosis is the main cause of CVD and future cardiovascular events. Ultrasound-based carotid artery imaging is a well-established surrogate imaging for coronary heart disease and is typically adopted in office-based settings. Studies have recently shown that image-based biomarkers or phenotypes when combined with conventional risk factors are even more effective in CVD risk prediction. Such image data, when collected or derived from a cohort, can be even more useful in predicting CVD risk. Recently such an approach setup for CVD risk assessment using the combination of carotid ultrasound plaque imaging and conventional cardiovascular risk factors (such as patients’ demographics and laboratory-based parameters) in the ML framework was proposed. Granularity in expressing CVD risk is crucial for personalized medicine and better drug monitoring. Thus, one can improve the system by using multiclass-multilabel-based (MCML) algorithms by assessing carotid ultrasound imaging for predicting the presence of significant coronary artery disease than traditional risk scoring methods. Specifically, our aims were to: (i) design a carotid image-based MCML CVD risk assessment calculator, (ii) study the effect of clustering risk predictors on MCML performance, and (iii) benchmark the MCML-based calculator against three types of conventional CVD risk calculators (CCVRC) such as the Framingham risk score, the systematic coronary risk evaluation score, and the atherosclerotic CVD score. The AtheroEdge 3.0 ML using camaging is reliable, accurate, and superior to traditional CVD risk scoring methods for predicting the CVD/stroke risk due to coronary artery disease.

(i) Implementation of Training System

For generating the training model, one needs to define the type of the training model based on the number of samples in the training system. This is done under the subsystem called cross-validation. Typically, the cross-validation is categorized by the symbol “K”. Examples of cross-validation systems are K2, K3, K4, K5, K10, and TT. K2 means 50% training and 50% testing data, K3 means 66% training data and 33% testing data, K4 means 75% training data and 25% testing data, K5 means 80% training data and 20% testing data, K10 means 90% training data and 10% testing data, and finally, TT means “Training equals Testing protocol”, where training data is 100% and testing data is also 100%. Typically, the TT protocol is adapted to validate the AI systems.

(ii) Implementation of Prediction System

This is the first study that combined conventional predictors with eight other clinical clusters of different features in an MCML using the coronary angiogram as the gold standard. Such a system can then leverage the cohort’s knowledge of nonlinearity between input predictors and the gold standard in an MCML framework by automatically and accurately predicting and stratifying the stroke/CVD risk into four granular classes. Thus, the AtheroEdge 3.0 MCML system uniquely overcomes such nonlinearity in a multiclass
framework, especially by using the carotid plaque image phenotypes, providing a powerful paradigm similar to an office-based setup, where only the offline training coefficients are needed for such an accurate prediction. To address the challenge of class imbalance in the dataset, which is the most common problem in medical datasets, we used the commonly used SMOTE algorithm that generated independent samples to balance each of the minority risk classes.

(iii) Performance

Our study was highly novel and has demonstrated the superior performance of the MCML-based algorithm compared with previous similar studies. We compared our study results with five recent ML-based studies using the AUC as a common performance evaluation metric. Recently, Kakadiaris et al. [38] have presented a 13-year follow-up study with 6459 participants to predict the CVD risk using an ML classifier and compared its performance against the ASCVD risk calculators. The authors performed binary CVD risk stratification using an SVM-based ML classifier with nine conventional CVD risk predictors and follow-up cardiovascular events as the gold standard.

(iv) Maintenance

Our system works using Python, and Java in a windows 11.0 platform and for maintenance of the system, the following items are kept in mind namely: upgrade of windows platform, upgrade of open-source python system, upgrade of Java system, upgrade of the database system from Oracle, update version of the PDF distiller as needed for report generation. Furthermore, there are bug trackers as usual, which are proprietary and cannot be shared or released.

5.6. Distribution Strategies of the Potential Benefits of the ML/AI Model

There are several distribution strategies for the potential benefits of commercial ML/AI models. Since AI models are online systems that need “test data sets” for execution, such models can be integrated into, (i) cloud-based settings, or (ii) embedded in the scanning devices, something like “Intel processor chip in Dell computer”.

The cloud-based strategies are most effective because the system can be executed from “any computer” and “any time”. The cloud-based system can be launched in offline settings and the ultrasonic data can be physically moved from the ultrasound machines to the “local computer”. This is one way the data can be distributed to the local computer and the benefit of ML/AI can be realized.

The second distribution strategy is when the offline training models can be embedded into the scanning devices that hold the data. This kind of distribution strategy raises the price of the system, and the cost of maintenance is high due to the evolution of the ML/DL model generations. The profits are high since AI models are embedded in the system itself. If the interface of the models is smooth and the graphical user interfaces are ergonomic or user-friendly, the overall systems can be very powerful. Such distribution strategies are compact but surely encounter a higher price tag for customers. The shipping of such scanners has higher maintenance costs and is typically passed to the customers. Upgrades are more frequent due to scientific evolutions, which are again passed to the customers.

No matter which distribution strategy one chooses for benefitting the AI models, “cloud vs. embedded-based solution”, and the interface design must incorporate multi-threaded and multi-tasking architectures enveloping higher CPU clock speed, preferably GPU-based settings or even pruned models having the explainable AI-based paradigms.

6. Critical Discussion

In this review, we focused on the CVD/Stoke risk stratification of PD patients in the COVID-19 framework. Furthermore, it is clear from a detailed evaluation of several investigations that PD patients with COVID-19 are at an elevated risk of CVD/stroke. As a result, in addition to COVID-19 on PD patients and its monitoring, a low-cost approach should be used to prevent a patient’s CVD/stroke symptoms from worsening. With the aid
of a DL-based AI model, these patients may be efficiently monitored, and long-term effects can be averted. In the presence of the COVID-19 framework, DL can assist in CVD/stroke risk stratification in PD patients, with improved sensitivity and specificity. Clinicians can use this model to counsel COVID-19-positive patients with PD along with carotid arterial imaging, and provide further guidance on the CVD/stroke risk.

6.1. Benchmarking

PD and COVID-19 have been linked in a few studies utilizing OBBM, LBBM, CUSIP, and MedUSE, according to an overview of the data. AI’s function in the diagnosis of joint COVID-19 and PD is rarely discussed in the literature. Only a few articles in the COVID-19 framework use the AI model to describe the severity of PD. Table 7 reports the benchmarking scheme for selected studies.

Table 7. Benchmarking scheme for selected studies.

| SN | S0 | COVID-19 Symptoms in PD Patients | PD Motor Symptoms | PD Non-Motor Symptoms | Risk Factors | Gold Standard |
|----|----|---------------------------------|------------------|----------------------|-------------|---------------|
|    |    | S1 | S2 | S3 | S4 | S5 | S6 | S7 | S8 | S9 | S10 | S11 | S12 | S13 | S14 | S15 | S16 |
| 1  |    | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  |
| 2  |    | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  |
| 3  |    | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  |
| 4  |    | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  |
| 5  |    | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  |
| 6  |    | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  |
| 7  |    | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  |
| 8  |    | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  |
| 9  |    | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  |
| 10 |    | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  |
| 11 |    | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  | ✓  |

S0: Author, S1: Fever, S2: Dry cough, S3: Cough, S4: Shortness of breath, S5: Pneumonia, S6: Delirium, S7: Bradykinesia, S8: Rigidity in throat muscles, S9: Anxiety, S10: Sleep disorder, S11: Hypertension, S12: Fainting, S13: Age, S14: PD duration, S15: PD with COVID-19 and comorbidities, S16: PD with COVID-19 mortality risk factor, ✓: Yes, ×: No.

6.2. Bias in Deep Learning Systems

The training model design step of the DL algorithms is highly dependent on the sample size employed. Furthermore, due to a lack of, (i) clinical testing of AI techniques, (ii) scientific validation, (iii) not satisfying the gold standard, (iv) comorbidities, (v) lack of big data configuration, and (vi) not judging the proper disease severity ratio, these all lead to bias in the AI. As a result, when COVID-19-associated PD symptoms (or risk factors) are examined as inputs into an AI model, it is critical that the AI model be stable, accurate, and has minimal AI bias [45,224,271−273]. It may also be noticed that the database contains geographically specific patient characteristics. As a result, the model may produce
deceptive positive or negative findings for other continents, introducing bias into the model [274,275].

6.3. The Economic Aspect of AI-Based Diagnosis

The field of artificial intelligence (AI) has an effect on virtually every aspect of life [32], particularly the application of machine learning and deep learning in medical imaging [32,276]. The use of AI in medical diagnostics is now in the early adoption phase across several different specialties [1]. The number of AI articles has increased exponentially. Willmen et al. [277] showed a cost-effective saving when using a referral system using decision support. One reason is the optimized, accurate, and automated solution. This directly transforms into cost benefits, leading to significant influence on the discipline of economics. Several examples have shown the cost benefits of AI in different applications of medicine.

Mital et al. [278] conducted a model-based economic evaluation that used a hybrid decision tree/microsimulation model for comparing the costs of screening mammography using eight different methods. The study showed that using AI in breast screening for low-risk women is the most cost-effective solution. Areia et al. [279] conducted the Markov model for colorectal cancer screening with and without AI. The study showed prevention of 7194 colorectal cancers along with prevention of 2089 deaths, and finally a saving of 290 million USD. According to a recent study on the internet of things (IoT), machine learning is helping to speed up the growth of industrial supply chains, which saves both time and money. Morrison et al. [280] developed a cost-effectiveness analysis of an AI-based solution [280] for retinopathy of prematurity (ROP) screening. The authors adapted the decision tree’s machine learning solutions and compared them against three different kinds of strategies such as ophthalmoscopy, telemedicine, and assistive AI with telemedicine review. The authors took a cohort of infants using ROP screening in the USA. The outcome of the study demonstrated the most cost-effective solution was using an AI-based telemedicine approach. The main reason for this was the avoidance of human examiners for detecting ROP. Bao et al. [281] showed the role of AI-based assisted reading of human papillomavirus (HPV) testing and compared it against liquid-based cytology and manually drawn readings. The study included 2065 women aged 25–64 proving their hypothesis that AI-based solutions are effective both in cost and efficiency. Hoshida et al. [282] demonstrated the cost-effectiveness of four types of hepatitis B virus (HBV) serological screening methods in China. The authors designed the Markov cohort model, by taking into consideration the parameters based on previous studies databases. Lee et al. [283] proposed an AI-based solution to faulty remote water-meter-reading (RWMR) devices. The authors adapted a convolutional neural network–long short-term memory network (CNN–LSTM) by considering 2762 customers over 360 days and collecting 2,850,000 AMI datasets in semi-rural areas of South Korea. The authors demonstrated an F-measure of 0.82 and Mathew coefficient of 0.83 using CNN–LSTM as part of the cost–benefit analysis.

Cardiovascular disease (CVD) is one of the major causes of mortalities and morbidities in the world [284]. Annually, CVD causes ~17.9 million mortalities each year [284]. From our survey, we did not find any cost–benefit analysis paper related to CVD. The early diagnosis of the risk of CVD/stroke is very important for reducing healthcare expenditures and saving lives. With AI, CVD detection can be performed early, faster, and at a low cost. Since only training models are needed that can be stored in the system, the online CVD/stroke risk prediction can be quickly done in seconds if the test patient data is available. This is highly economic since the risk stratification can be done in seconds with granularity. Rural areas are seeing a decline in the number of primary care physicians employed there. This is because rural families, on average, earn less money than families living in urban areas. Because AI can provide specific test support in place of procedures, it can help address the challenges brought about by changes in both the demographics and the economy. Now with the cloud-based internet solution, the data can be simply loaded onto the web and the system by calling the offline models to predict the risk of granularity.
for CVD/stroke. This saves tremendous amounts of time and, thus, eventually the cost is lower [285].

For CVD/stroke risk prediction in PD patients in the COVID-19 framework, the same set of AI benefits apply here as well. The deep learning automated model can be used for COVID-19 detection and quantification in CT scans [286]. This is fully automated and a superior time-saver, which translates into cost savings. The covariate design for ML-based CVD/stroke risk prediction is a further time-saver, since it can be used for training model one-time design. These models can then be used for CVD/stroke risk prediction on online patients, further saving time and cost. The various deep convolutional neural network architectures were explained in Appendix A.

In summary, the main attributes of economic benefits for using AI-based solutions are, (i) early detection of the disease, (ii) prevention of surgery at a delayed time, (iii) use of off-line in-built training models embedded in the systems, and (iv) Usage of cloud-based AI technologies. While AI is powerful and proving to be an economic solution, there are ethical concerns [287], lack of regulation, and handing of AI bias [216,271–273,288]. Further, these solutions should use big data framework [274] and blockchain framework [289] if AI is taken to its full advantage.

6.4. Strengths, Weakness, and Extensions

The main strength of the current system is the role of DL for CVD/stroke risk assessment in PD patients in the presence of COVID-19. DL offers better training and risk prediction due to superior non-linear adjustment between the covariates and the gold standard. Further, the system offers better coverage of covariates such as OBBM, LBBM, CUSIP, MedUSE, PD covariates, and COVID-19 covariates along with lesion sizes estimated from the CT scans of the lungs. Further, the role of LSTM, a very powerful approach for the DL system design for CVD/stroke risk prediction was presented. Lastly, the DL system is generalized which can be altered by adding more covariates and comorbidities such as diabetes, rheumatoid arthritis, renal disease, coronary artery disease, etc.

The AI-based solution for CVD/stroke risk assessment of PD patients in COVID-19 framework is the first to introduce the use of a machine learning system for CVD/stroke risk assessment and is easily amendable for adjustment of more parameters. This means more covariates can be added and the machine learning system will perform better once optimized. The deep learning paradigms are powerful solutions for lesion detection.

The first time the system is developed it computes CVD/stroke risk in PD patients in the COVID-19 framework.

While DL offers strengths to the system, it also needs to be ensured that the system is optimized always. This requires several iterations of hit-and-trial attempts to achieve optimal DL solutions. Further, the DL system requires a solid gold standard for, (a) during CT lesion annotations, and (b) CVD/stroke gold standard collection in cohorts, which also requires time and cost. Lastly, as pointed out before, DL systems are susceptible to AI bias due to overperformance in terms of accuracy and lack of interpretability. In terms of extensions, superior DL systems can be designed using ensemble-based methods. Big data can be considered as an option for improving the DL system by taking more sources of data and in a larger sample size. The DL system can be improved by adding the augmentation designs should the cohort size be small. Lastly, the new wave of pruning needs to be incorporated into the DL system for smaller-size training storage models [290] and evolutionary methods [291].

7. Conclusions

The importance of CVD/stroke risk prediction for PD patients in the COVID-19 environment was highlighted in this comprehensive investigation. We also illustrated how PD with COVID-19 can cause vascular and cerebral strokes. This review highlighted how PD with COVID-19 may aggravate complexity in CVD/stroke. Thus, PD patients’ CVD/stroke risk categorization in the COVID-19 paradigm is critical. Carotid imaging is a
non-invasive, low-cost alternative to conventional imaging for monitoring CVD/stroke in PD patients. This low-cost B-mode ultrasonography also will help characterize plaque tissue in PD patients with COVID-19, improving CVD/stroke risk assessment. CT scan images of lung lesions can help diagnose and quantify COVID-19 infection severity, which is useable as a covariate during DL design. As a result, we explained the role of an AI-based model that can be used to accurately classify PD patients into risk groups for CVD/stroke based on their COVID-19 risk profile. The COVID-19 framework was used to describe an AI-based model for predicting CVD/stroke risk in PD patients. Finally, we discussed the involvement of joint PD with COVID-19 in the CVD/stroke paradigm, as well as the role of AI in this context.

Author Contributions: Conceptualization, J.S.S., M.A.M. and. S.P.; Methodology and software, J.S.S., M.A.M., L.S., M.B. and M.T. Validation, A.J., M.T., P.A., L.M.S., G.F. and N.N.K.; Investigation, P.S.C., K.V., J.R.L., K.I.P., M.S., M.T., S.M., M.M., M.T., D.W.S. and J.S.S.; Resources, S.P.; Data curation, M.A.M., L.S., S.P., T.O., G.D.K. and J.S.S.; Writing—original draft preparation, S.P., M.A.M., L.S., M.A.-M., P.R.K., M.K., D.W.S., M.M.F., S.N. and J.S.S.; Writing—review and editing, S.P., M.A.M., L.S., M.T., M.S., A.B., V.A., P.P.S., A.J., P.R.K. and J.S.S.; Visualization, D.P.M., A.A., S.S., S.K.D., K.V., R.K., J.S.T., A.S. (Aditya Sharma), G.T., Z.R., A.D.P., A.N. and J.S.S.; Supervision, S.M., A.S. (Ajit Saxena), V.R., V.A., M.F. and J.S.S.; Project administration, S.P., N.N.K., J.S.T., P.P.S. and J.S.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Suri is with AtheroPoint™ LLC, Roseville, CA, USA, which does cardiovascular and stroke imaging.

Data Availability Statement: No data availability.

Acknowledgments: Mahesh A. Maindarkar, would like to acknowledge the Department of Science and Technology, Government of India for sponsoring the project under the scheme IMPRINT-2 vide file no: IMP/2018/000034, Dated: 28 March 2019.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| SN | Abb | Definition |
|----|-----|-----------|
| 1  | A1c | Glycated hemoglobin |
| 2  | ANS | Autonomic nervous system |
| 3  | ANN | Artificial neural network |
| 4  | ACE2 | Angiotensin converting enzyme 2 |
| 5  | AUC | Area under the curve |
| 6  | AI  | Artificial intelligence |
| 7  | ARDS | Acute respiratory distress syndrome |
| 8  | BMI | Body mass index |
| 9  | CAD | Coronary artery disease |
| 10 | CAS | Coronary artery syndrome |
| 11 | CCA | Circumflex coronary artery |
| 12 | CPD | Chorionic pulmonary disease |
| 13 | COPD | Chronic obstructive pulmonary disease |
| 14 | CKD | Chronic kidney disease |
| 15 | CT  | Computed tomography |
| 16 | CUSIP | Carotid ultrasound image phenotype |
| 17 | CV  | Cross-validation |
| 18 | CVD | Cardiovascular disease |

| SN | Abb | Definition |
|----|-----|-----------|
| 19 | AUC | Area under the curve |
| 20 | AI  | Artificial intelligence |
| 21 | ARDS | Acute respiratory distress syndrome |
| 22 | BMI | Body mass index |
| 23 | CAD | Coronary artery disease |
| 24 | CAS | Coronary artery syndrome |
| 25 | CCA | Circumflex coronary artery |
| 26 | CPD | Chorionic pulmonary disease |
| 27 | COPD | Chronic obstructive pulmonary disease |
| 28 | CKD | Chronic kidney disease |
| 29 | CT  | Computed tomography |
| 30 | CUSIP | Carotid ultrasound image phenotype |
| 31 | CV  | Cross-validation |
| 32 | CVD | Cardiovascular disease |

| SN | Abb | Definition |
|----|-----|-----------|
| 33 | VCAM | Vascular cell adhesion molecule |
| 34 | LBBM | Laboratory-based biomarker |
| 35 | LDL | Low-density lipoprotein |
| 36 | LSTM | Long short-term memory |
| 37 | MedUSE | Medication use |
| 38 | ML | Machine learning |
| 39 | NB | Naive bayes |
| 40 | MRI | Magnetic resonance imaging |
| 41 | NPV | Negative predictive value |
| 42 | NN | Neural networks |
| 43 | nOH | Neurogenic orthostatic hypotension |
| 44 | Non-ML | Non-machine learning |
| 45 | NR | Not reported |
| 46 | NO | Nitric oxide |
| 47 | OBBM | Office-based biomarker |
| 48 | OH | Orthostatic hypotension |
| 49 | PD | Parkinson’s disease |
| 50 | PE | Performance evaluation matrices |
Appendix A

Appendix A.1. Deep Convolutional Neural Network Architecture

Figure A1 shows DCNN’s global architecture. It has four convolution layers and an average pooling layer. The 2D feature map is then flattened to create a 1D map. Two 128-node hidden layers follow. The “Softmax” layer has two nodes representing symptomatic and asymptomatic classes.

Figure A1. The general structure of CNN architecture (courtesy of AtheroPoint™, Roseville, CA, USA) [292].

Appendix A.2. DenseNet Architecture

DenseNet architecture solves deep neural nets vanishing gradient problems. This model included dense blocks. It has a pool of convolution layers with $3 \times 3$ filters to $1 \times 1$ filters followed by batch normalization (BN) and every layer employs “ReLU” activation. These dense blocks were concatenated using transition blocks. Each transition block includes $2 \times 2$ to $1 \times 1$ filters with dropout layers, convolution, and pooling layers. The beauty of DenseNet is that there are parallel connections to avoid losing the features.
Figure A2. The general structure of DenseNet architecture (courtesy of AtheroPoint™, Roseville, CA, USA) [292].

Appendix A.3. Inception V3 Architecture

This model was created to reduce calculation time and parameters. This model handles large datasets. This model is efficient. When using ImageNet, Inception V3 achieves higher accuracy. The model has blocks. Convolution and max-pooling layers are included. Figure A3 shows architecture, DL1 to DL6 as depth-wise convolution, C1 as initial convolution, T1 to T3 as transition layer, and D1 to D4 as batch normalization. In Inception V3, each top-row block represents rows 2 and 3. Row 2 repeats row 3. Each convolution layer has a stride 1 and padding 0 convolution filter. First, a 3 × 3 convolution layer with stride 1 and padding 1 is added to the feature map (FM). It reduces FM depth; the resultant FM and initial FM are fused to make row 2 blocks.

Figure A3. The general structure of InceptionV3 architecture [292].

Appendix A.4. Xception Net Architecture

A modification to IV3 was suggested by Chollet et al. from Google. This modification would involve replacing the inception modules with modified depth-wise separable convolution layers. There are a total of 36 strata in this architecture. XceptionNet is lightweight compared to IV3, and it contains the same number of parameters as IV3. The top-1 accuracy of this architecture is 0.790, and the top-5 accuracy is 0.945, which is better than InceptionV3’s performance. The Xception system’s architecture is depicted in Figure A4.
Appendix A.5. Resnet50 Architecture

To solve the vanishing gradient problem the ResNet model is used. Skip connections are in residual blocks. These skip connections skip training levels and output links. Skipping layers allows the model to learn complex patterns. This TL model uses CIFAR-10 data, unlike others. Figure A5 depicts ResNet. Architecture pairs two $3 \times 3$ convolution layers. These pairs’ outputs and inputs are combined and fed to the following pair. Here, 64–512 filters are listed. After the last $3 \times 3$ convolution layer with 512 filters and a flattened layer for vectorizing 2D features, the output is predicted using softmax activation.

Appendix A.6. MobileNet Architecture

This was the first computer vision model developed for TensorFlow for mobile devices. It contains 28 layers and uses the TFlite (database) library. Figure A6 presents the architecture of MobileNet architecture. This model contains bottleneck residual blocks (BRBs), also referred to as inverted residual blocks used for reducing the number of training parameters in the model.
Appendix A.7. AlexNet Architecture

Alex Krizhevsky et al. suggested AlexNet for ImageNet in 2012. It is CNN’s initial architecture for computer vision challenges. This architecture’s error rate is 15.3%. This architecture transforms AI. It accepts 256x256 images and has five convolution layers and two completely connected networks. Softmax output layer. Sample architecture is shown in Figure A7.

Appendix A.8. SuriNet Architecture

The first is a more traditional CNN, and the second is an architecture known as SuriNet. Although the UNet network is often used for segmentation in medical image analysis, the SuriNet architecture, which is a modified version of the UNet architecture, was the one that we relied on for classification. We employed separable convolution neural networks in the SuriNet architecture that we suggested to cut down on the amount of overfitting and the number of parameters that were necessary for training. The architecture of SuriNet is depicted in Figure A8.
Diagnostics 2022, 12, 1543

Figure A8. SuriNet architecture [292].

References

1. Bhat, S.; Acharya, U.R.; Hagiwara, Y.; Dadmehr, N.; Adeli, H. Parkinson’s disease: Cause factors, measurable indicators, and early diagnosis. Comput. Biol. Med. 2018, 102, 234–241. [CrossRef] [PubMed]

2. Cilia, R.; Bonvegna, S.; Straccia, G.; Andreasi, N.G.; Elia, A.E.; Romito, L.M.; Devigili, G.; Cereda, E.; Eleopra, R. Effects of COVID-19 on Parkinson’s disease clinical features: A community-based case-control study. J. Mov. Disord. 2020, 35, 1287–1292. [CrossRef] [PubMed]

3. Shimoda, A.; Li, Y.; Hayashi, H.; Kondo, N. Dementia risks identified by vocal features via telephone conversations: A novel machine learning prediction model. PLoS ONE 2021, 16, e0253988. [CrossRef] [PubMed]

4. Sulzer, D.; Antonini, A.; Leta, V.; Nordvig, A.; Smeyne, R.J.; Goldman, J.E.; Al-Dalahmah, O.; Zecca, L.; Sette, A.; Bubacco, L. COVID-19 and possible links with Parkinson’s disease and parkinsonism: From bench to bedside. npj Parkinson’s Dis. 2020, 6, 18. [CrossRef]

5. Khoshnood, R.J.; Zali, A.; Tafreshinejad, A.; Ghajarzadeh, M.; Ebrahimi, N.; Safari, S.; Mirmosayyeb, O. Parkinson’s disease and COVID-19: A systematic review and meta-analysis. Neurol. Sci. 2021, 43, 775–783. [CrossRef]

6. Helmich, R.C.; Bloem, B.R. The impact of the COVID-19 pandemic on Parkinson’s disease: Hidden sorrows and emerging opportunities. J. Parkinson’s Dis. 2020, 10, 351. [CrossRef]

7. Baschi, R.; Luca, A.; Nicoletti, A.; Caccamo, M.; Cicero, C.E.; D’Agate, C.; di Giorgi, L.; la Bianca, G.; Castro, T.L.; Zappia, M. Changes in motor, cognitive, and behavioral symptoms in Parkinson’s disease and mild cognitive impairment during the COVID-19 lockdown. J. Front. Psychiatry 2020, 11, 590134. [CrossRef]

8. Maniruzzaman, M.; Kumar, N.; Abedin, M.M.; Islam, M.S.; Suri, H.S.; El-Baz, A.S.; Suri, J.S. Comparative approaches for classification of diabetes mellitus data: Machine learning paradigm. Comput. Methods Programs Biomed. 2017, 152, 23–34. [CrossRef]

9. Schrag, A.; Jahanshahi, M.; Quinn, N.P. What contributes to depression in Parkinson’s disease? Psychol. Med. 2001, 31, 65–73. [CrossRef]

10. Reijnders, J.S.; Ehrt, U.; Weber, W.E.; Aarsland, D.; Leentjens, A.F. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov. Disord. 2008, 23, 183–189. [CrossRef]

11. McKeith, I.G.; Burn, D. Spectrum of Parkinson’s disease, Parkinson’s dementia, and Lewy body dementia. Neurol. Clin. 2000, 18, 865–883. [CrossRef]

12. Noe, E.; Marder, K.; Bell, K.L.; Jacobs, D.M.; Manly, J.J.; Stern, Y. Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia. Mov. Disord. 2004, 19, 60–67. [CrossRef]

13. Minagi, S.; Matsunaga, T.; Shibata, T.; Sato, T.S. An appliance for management of TMJ pain as a complication of Parkinson’s disease. CRANIO® 1998, 16, 57–59. [CrossRef]

14. Van Camp, G.; Flamez, A.; Cosyns, B.; Weytjens, C.; Muyldermans, L.; van Zandijcke, M.; de Sutter, J.; Santens, P.; Decoodt, P.; Moerman, C. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvar heart disease. Lancet 2004, 363, 1179–1183. [CrossRef]

15. Devos, D.; Kroumova, M.; Bordet, R.; Vodounough, H.; Guieu, J.; Libersa, C.; Destee, A. Heart rate variability and Parkinson’s disease severity. J. Neural Transm. 2003, 110, 997–1011.

16. Lau, Y.H.; Lau, K.M.; Ibrahim, N.M. Management of Parkinson’s Disease in the COVID-19 Pandemic and Future Perspectives in the Era of Vaccination. J. Mov. Disord. 2021, 14, 177. [CrossRef]

17. Porcu, M.; Sanfilippo, R.; Montisci, R.; Balestrieri, A.; Suri, J.S.; Wintermark, M.; Saba, L. White-matter hyperintensities in patients with carotid artery stenosis: An exploratory connectometry study. Neuroradiol. J. 2020, 33, 486–493. [CrossRef]

18. Elbaz, A.; Bower, J.H.; Peterson, B.J.; Maraganore, D.M.; McDonnell, S.K.; Ahlskog, J.E.; Schaid, D.J.; Rocca, W.A. Survival study of Parkinson disease in Olmsted county, Minnesota. Arch. Neurol. 2003, 60, 91–96. [CrossRef]

19. Pohar, S.L.; Jones, C.A. The burden of Parkinson disease (PD) and concomitant comorbidities. Arch. Gerontol. Geriatr. 2009, 49, 317–321. [CrossRef]
45. Saba, L.; Gerosa, C.; Wintermark, M.; Hedin, U.; Fanni, D.; Suri, J.S.; Balestrieri, A.; Faa, G. Can COVID-19 trigger the plaque

46. Agarwal, M.; Saba, L.; Gupta, S.K.; Carriero, A.; Falaschi, Z.; Paschê, A.; Danna, P.; El-Baz, A.; Naidu, S.; Suri, J.S. A Novel Block Imaging Technique Using Nine Artificial Intelligence Models for COVID-19 Disease Classification, Characterization and Severity Measurement in Lung Computed Tomography Scans on an Italian Cohort. J. Med. Syst. 2021, 45, 28. [CrossRef]

47. Suri, J.S.; Agarwal, S.; Gupta, S.K.; Puvvula, A.; Viskovic, K.; Suri, N.; Alizad, A.; El-Baz, A.; Saba, L.; Fatemi, M.; et al. Systematic Review of Artificial Intelligence in Acute Distress Syndrome for COVID-19 Lung Patients: A Biomedical Imaging Perspective. IEEE J. Biomed. Health Inform. 2021, 25, 4128–4139. [CrossRef]

48. Meerson, F.Z.; Kagan, V.E.; Kozlov, Y.P.; Belkina, L.M.; Arkhipenko, Y.V. The role of lipid peroxidation in pathogenesis of ischemic damage and the antioxidant protection of the heart. Basic Res. Cardiol. 1982, 77, 465–485. [CrossRef]

49. Battineni, G.; Chintalapudi, N.; Amenta, F.; Traini, E. A Comprehensive Machine-Learning Model Applied to Magnetic Resonance Imaging (MRI) to Predict Alzheimer’s Disease (AD) in Older Subjects. J. Clin. Med. 2020, 9, 2146. [CrossRef]

50. Janghel, R.R.; Shukla, A.; Rathore, C.P.; Verma, K.; Rathore, S. A comparison of soft computing models for Parkinson’s disease diagnosis using voice and gait features. Netw. Model. Anal. Health Inform. Bioinform. 2017, 6, 14. [CrossRef]

51. Derespina, K.; Kaushik, S.; Plichta, A.; Conway, E.E.; Bercow, A.; Choi, J.; Eisenberg, R.; Gillen, J.; Sen, A.I.; Hennigan, C.M.; et al. Clinical Manifestations and Outcomes of Critically Ill Children and Adolescents with Coronavirus Disease 2019 in New York City. J. Pediatr. 2020, 226, 55–63.e2. [CrossRef] [PubMed]

52. Saba, L.; Gerosa, C.; Wintermark, M.; Hedin, U.; Fanni, D.; Suri, J.S.; Balestrieri, A.; Faa, G. Can COVID19 trigger the plaque vulnerability—A Kounis syndrome warning for asymptomatic subjects. Cardiovasc. Diag. Ther. 2020, 10, 1352. [CrossRef]

53. Ciceri, F.; Castagna, A.; Rovere-Querini, P.; De Cobelli, F.; Ruggeri, A.; Galli, L.; Conte, C.; De Lorenzo, R.; Poli, A.; Ambrosio, A.; et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin. Immunol. 2020, 217, 108509. [CrossRef] [PubMed]

54. Janghel, R.R.; Shukla, A.; Rathore, C.P.; Verma, K.; Rathore, S. A comparison of soft computing models for Parkinson’s disease diagnosis using voice and gait features. Netw. Model. Anal. Health Inform. Bioinform. 2017, 6, 14. [CrossRef] [PubMed]

55. Saba, L.; Gerosa, C.; Wintermark, M.; Hedin, U.; Fanni, D.; Suri, J.S.; Balestrieri, A.; Faa, G. Can COVID-19 trigger the plaque vulnerability—A Kounis syndrome warning for asymptomatic subjects. Cardiovasc. Diag. Ther. 2020, 10, 1352. [CrossRef]

56. Suri, J.S.; Agarwal, S.; Gupta, S.K.; Puvvula, A.; Viskovic, K.; Suri, N.; Alizad, A.; El-Baz, A.; Saba, L.; Fatemi, M.; et al. Systematic Review of Artificial Intelligence in Acute Distress Syndrome for COVID-19 Lung Patients: A Biomedical Imaging Perspective. IEEE J. Biomed. Health Inform. 2021, 25, 4128–4139. [CrossRef]

57. Meerson, F.Z.; Kagan, V.E.; Kozlov, Y.P.; Belkina, L.M.; Arkhipenko, Y.V. The role of lipid peroxidation in pathogenesis of ischemic damage and the antioxidant protection of the heart. Basic Res. Cardiol. 1982, 77, 465–485. [CrossRef]

58. Antonini, A.; Leta, V.; Teo, J.; Chaudhuri, K.R. Outcome of Parkinson’s disease patients affected by COVID-19. Mov. Disord. 2020. [CrossRef]

59. Antonelli, A.; Bennardo, F.; Brancaccio, Y.; Barone, S.; Femiano, F.; Nucci, L.; Minervini, G.; Fortunato, L.; Attanasio, F.; Giudice, A. Can Bone Compaction Improve Primary Implant Stability? An In Vitro Comparative Study with Osseodensification Technique. Appl. Sci. 2020, 10, 8623. [CrossRef]

60. Saba, L.; Gerosa, C.; Wintermark, M.; Hedin, U.; Fanni, D.; Suri, J.S.; Balestrieri, A.; Faa, G. Can COVID-19 trigger the plaque vulnerability—A Kounis syndrome warning for asymptomatic subjects. Cardiovasc. Diag. Ther. 2020, 10, 1352. [CrossRef]

61. Janghel, R.R.; Shukla, A.; Rathore, C.P.; Verma, K.; Rathore, S. A comparison of soft computing models for Parkinson’s disease diagnosis using voice and gait features. Netw. Model. Anal. Health Inform. Bioinform. 2017, 6, 14. [CrossRef] [PubMed]

62. Ciceri, F.; Castagna, A.; Rovere-Querini, P.; De Cobelli, F.; Ruggeri, A.; Galli, L.; Conte, C.; De Lorenzo, R.; Poli, A.; Ambrosio, A.; et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin. Immunol. 2020, 217, 108509. [CrossRef] [PubMed]

63. Meerson, F.Z.; Kagan, V.E.; Kozlov, Y.P.; Belkina, L.M.; Arkhipenko, Y.V. The role of lipid peroxidation in pathogenesis of ischemic damage and the antioxidant protection of the heart. Basic Res. Cardiol. 1982, 77, 465–485. [CrossRef]
71. Amarenco, P.; Cohen, A.; Tzourio, C.; Bertrand, B.; Hommel, M.; Besson, G.; Chauvel, C.; Touboul, P.-J.; Bousser, M.-G. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. *N. Engl. J. Med.* 1994, 331, 1474–1479. [CrossRef]

72. Ikeda, N.; Gupta, A.; Dey, N.; Bose, S.; Shafique, S.; Arak, T.; Godia, E.C.; Saba, L.; Laird, J.R.; Nicolaides, A. Improved correlation between carotid and coronary atherosclerosis SYNTAX score using automated ultrasound carotid bulb plaque IMT measurement. *Ultrasound Med. Biol.* 2015, 41, 1247–1262. [CrossRef]

73. Peterson, E.; Lo, K.B.; DeJoy, R.; Salacup, G.; Pelayo, J.; Bhargav, R.; Gul, F.; Albano, J.; Azmaiparashvili, Z.; Amanullah, A. The relationship between coronary artery disease and clinical outcomes in COVID-19: A single-center retrospective analysis. *Coron. Artery Dis.* 2020, 32, 367–371. [CrossRef]

74. Szarpak, L.; Mierzejewska, M.; Jurk, J.; Kochanowska, A.; Gaszka, A.; Truszewski, Z.; Pruc, M.; Blek, N.; Rafique, Z.; Filipiak, K. Effect of Coronary Artery Disease on COVID-19—Prognosis and Risk Assessment: A Systematic Review and Meta-Analysis. *Biologia* 2022, 11, 221. [CrossRef]

75. Saba, L.; Sanfilippo, R.; Sanna, S.; Anzidei, M.; Montisci, R.; Mallarini, G.; Suri, J.S. Association Between Carotid Artery Plaque Volume, Composition, and Uteration: A Retrospective Assessment with MDCT. *Am. J. Roentgenol.* 2012, 199, 151–156. [CrossRef]

76. Araki, T.; Ikeda, N.; Shukla, D.; Jain, P.K.; Londohe, N.D.; Shrivastava, V.K.; Banchhor, S.K.; Saba, L.; Nicolaides, A.; Shafique, S. PCA-based polling strategy in machine learning framework for coronary artery disease risk assessment in intravascular ultrasound: A link between carotid and coronary grayscale plaque morphology. *Comput. Methods Programs Biomed.* 2016, 128, 137–158. [CrossRef]

77. Barman, H.A.; Atici, A.; Sahin, I.; Alici, G.; Tekin, E.A.; Baycan, F.; Ozturk, F.; Oflar, E.; Tugrul, S.; Yavuz, M.B.; et al. Prognostic significance of cardiac injury in COVID-19 patients with and without coronary artery disease. *Coron. Artery Dis.* 2020. [CrossRef]

78. Cao, C.; Li, D.; Zhan, S.; Zhang, C.; Sun, B.; Litvak, V. L-dopa treatment increases oscillatory power in the motor cortex of Parkinson’s disease patients. *NeuroImage Clin.* 2020, 26, 102–116. [CrossRef]

79. Blesa, J.; Trigo-Damas, I.; Quiroga-Varela, A.; Jackson-Lewis, V.R. Oxidative stress and Parkinson’s disease. *Parkinson’s Dis. Cell Vulnerability Dis. Prog.* 2016. [CrossRef]

80. Raees, P.C.M.; Thomas, V. Automated detection of Alzheimer’s Disease using Deep Learning in MRI. *J. Phys. Conf. Ser.* 2021, 1921, 012024. [CrossRef]

81. Priya, S.J.; Rani, A.J.; Subbathra, M.; Mohammed, M.A.; Damaševičius, R.; Ubendran, N. local pattern transformation based feature extraction for recognition of Parkinson’s disease based on gait signals. *Diagnostics* 2021, 11, 1395. [CrossRef]

82. Chen, R.; Kumar, S.; Garg, R.R.; Lang, A.E. Impairment of motor cortex activation and deactivation in Parkinson’s disease. *Clin. Neurophysiol.* 2001, 112, 600–607. [CrossRef]

83. Chen, T.; Mirzadeh, Z.; Chapple, K.M.; Lambert, M.; Shill, H.A.; Moguel-Cobos, G.; Tröster, A.I.; Dhall, R.; Ponce, F.A. Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease. *J. Neurosurg.* 2018, 130, 109–120. [CrossRef]

84. Gill, S.; Mouches, P.; Hu, S.; Rajashekar, D.; MacMaster, F.P.; Smith, E.E.; Forkert, N.D.; Ismail, Z. Using Machine Learning to Predict Dementia from Neuropsychiatric Symptoms and Neuroimaging Data. *J. Alzheimer’s Dis.* 2020, 75, 277–288. [CrossRef]

85. Zappia, M.; Annesi, G.; Nicoletti, G.; Arabia, G.; Annesi, F.; Messina, D.; Pugliese, P.; Spadafora, P.; Tarantino, P.; Carrideo, S. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskiniesias in Parkinson disease: An exploratory study. *Arch. Neurol.* 2005, 62, 601–605. [CrossRef]

86. Khan, S.; Gill, S.; Mooney, L.; White, P.; Whone, A.; Brooks, D.; Pavese, N. Combined pedunculopontine-subthalamic stimulation in Parkinson disease. *Neurology* 2012, 78, 1090–1095. [CrossRef] [PubMed]

87. Değirmenci, H.; Bakirci, E.M.; Hamur, H. Coronary Effects of Parkinson’s Disease. *Open J. Parkinson’s Dis. Treat.* 2020, 11, 72–78. [CrossRef] [PubMed]

88. Scherder, E.; Herr, K.; Pickering, G.; Gibson, S.; Benedetti, F.; Lautenbacher, S. Pain in dementia. *Pain* 1999, 331, 1474–1479. [CrossRef]

89. Alzubaidi, M.; Shah, U.; Zayadi, H.D.; Dolaat, K.; Abd-Alrazaq, A.; Ahmed, A.; House, M. The Role of Neural Network for the Detection of Parkinson’s Disease: A Scoping Review. *Healthcare* 2021, 9, 740. [CrossRef] [PubMed]

90. Poeoe, W.; Seppi, K.; Tanner, C.M.; Halliday, G.M.; Brundin, P.; Volkman, J.; Schrag, A.-E.; Lang, A.E. Parkinson disease. *Nat. Rev. Dis. Primers* 2017, 3, 17013. [CrossRef]

91. Olanow, C.W.; Stern, M.B.; Sethi, K. The scientific and clinical basis for the treatment of Parkinson disease (2009). *Neurology* 2009, 72, S1–S136. [CrossRef]

92. Çubukçu, H.C.; Yurtdağ, M.; Durak, Z.E.; Aytaç, B.; Güneş, H.N.; Çokal, B.G.; Yoldaş, T.K.; Durak, İ. Oxidative and nitrosative stress in serum of patients with Parkinson’s disease. *Neurosci. Lett.* 2016, 57, 1793–1798. [CrossRef]

93. Yan, L.-Y.; He, Q.-F.; Lu, M.-Y.; Wang, S.-L.; Qi, Z.-Q.; Dong, H.-R. Association between carotid plaque and Parkinson’s disease. *Ann. Transl. Med.* 2019, 7, 94. [CrossRef]

94. Guo, T.; Fan, Y.; Chen, M.; Wu, X.; Zhang, L.; He, T.; Wang, H.; Wan, J.; Wang, X.; Lu, Z. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol.* 2020, 5, 811–818. [CrossRef]

95. Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* 2020, 46, 846–848. [CrossRef]

96. Metzler, B.; Lechner, I.; Reindl, M.; Reinstadler, S.J. Cardiac injury after COVID-19: Primary cardiac and primary non-cardiac etiology makes a difference. *Int. J. Cardiol.* 2021, 350, 17–18. [CrossRef]

97. Sisto, T.; Isola, J. Incidence of atherosclerosis in the internal mammary artery. *Ann. Thorac. Surg.* 1989, 47, 884–886. [CrossRef]

98. Buob, A.; Winter, H.; Kindermann, M.; Becker, G.; Möller, J.C.; Oertel, W.H.; Böhm, M. Parasympathetic but not sympathetic cardiac dysfunction at early stages of Parkinson’s disease. *Clin. Res. Cardiol.* 2010, 99, 701–706. [CrossRef] [PubMed]
125. Cenci, M.A.; Crossman, A.R. Animal models of l-dopa-induced dyskinesia in Parkinson’s disease. Mov. Disord. 2018, 33, 889–899. [CrossRef]

126. Chagraoui, A.; Boullain, M.; Juvin, L.; Anouar, Y.; Barrière, G.; Deurwaerdère, P.D. L-dopa in Parkinson’s disease: Looking at the false neurotransmitters and their meaning. Int. J. Mol. Sci. 2020, 21, 294. [CrossRef] [PubMed]

127. Blackwell, D.J.; Faggioni, M.; Wlekliński, M.J.; Gómez-Hurtado, N.; Venkataraman, R.; Gibb, C.E.; Baudenbacher, F.J.; Gong, S.; Fishman, G.I.; Boyle, P.M.; et al. The Purkinje–myocardial junction is the anatomical origin of ventricular arrhythmia in CPVT. JCI Insight 2022, 7, e151893. [CrossRef] [PubMed]

128. Acharya, U.R.; Joseph, K.P.; Kannathal, N.; Min, L.C.; Suri, J.S. Heart rate variability. Adv. Card. Signal Process. 2007, 121–165.

129. Ferini-Strambi, L.; Salson, M. COVID-19 and neurological disorders: Are neurodegenerative or neuroinflammatory diseases more vulnerable? J. Neurol. 2020, 268, 409–419. [CrossRef]

130. Sorbora, C.; Brigandi, A.; Cimino, V.; Bonanno, L.; Ciurleo, R.; Bramanti, P.; Di Lorenzo, G.; Marino, S. The impact of SARS-CoV2 infection on people in residential care with Parkinson Disease or parkinsonisms: Clinical case series study. PLoS ONE 2021, 16, e0251313. [CrossRef]

131. Ishiyama, H.; Ishii, J.; Yoshimura, H.; Tsunogae, M.; Fujiwara, S.; Hiya, S.; Inui, R.; Shiomi, Y.; Nakazawa, S.; Kimura, M.; et al. Neurological Manifestations and Long-term Sequelae in Hospitalized Patients with COVID-19. Intern. Med. 2022. [CrossRef]

132. Cau, R.; Pacielli, A.; Fatemeh, H.; Vaudano, P.; Arru, C.; Crivelli, P.; Stranieri, G.; Suri, J.S.; Manneli, L.; Conti, M. Complications in COVID-19 patients: Characteristics of pulmonary embolism. Clin. Imaging 2021, 77, 244–249. [CrossRef]

133. Studer, V.; Rocchi, C.; Motta, C.; Lauretti, B.; Perugini, J.; Brambilla, L.; Pareja-Gutierrez, L.; Camera, G.; Barbieri, F.R.; Marfia, G.A.; et al. Heart rate variability is differentially altered in multiple sclerosis: Implications for acute, worsening and progressive disability. Mult. Scler. J. Exp. Transl. Clin. 2017, 3. [CrossRef]

134. Vascellari, S.; Melis, M.; Pisanu, S.; Cusano, R.; Uva, P.; Madau, V.; Sarchioto, M.; Oppo, V.; et al. Gut microbiota and metabolome alterations associated with Parkinson’s disease. Msystems 2020, 5, e00561-20. [CrossRef]

135. Rickards, H. Depression in neurological disorders: Parkinson’s disease, multiple sclerosis, and stroke. J. Neurol. Neurosurg. Psychiatry 2005, 76 (Suppl. 1), 148–152. [CrossRef]

136. Mastaglia, F.L.; Johnsen, R.D.; Kakulas, B.A. Prevalence of stroke in Parkinson’s disease: A postmortem study. Mov. Disord. 2002, 17, 772–774. [CrossRef]

137. Adams, W.R. High-accuracy detection of early Parkinson’s Disease using multiple characteristics of finger movement while typing. PLoS ONE 2017, 12, e0188226. [CrossRef]

138. Cau, R.; Bassareo, P.P.; Manneli, L.; Suri, J.S.; Saba, L. Imaging in COVID-19-related myocardial injury. Int. J. Cardiovasc. Imaging 2021, 37, 1349–1360. [CrossRef]

139. Maniruzzaman; Rahman, J.; Hasan, A.M.; Suri, H.S.; Abedin, M.; El-Baz, A.; Suri, J.S. Accurate Diabetes Risk Stratification Using Machine Learning: Role of Missing Value and Outliers. J. Med. Syst. 2021, 45, 278. [CrossRef]

140. Banchhor, S.K.; Londhe, N.D.; Araki, T.; Saba, L.; Radeva, P.; Laird, J.R.; Suri, J.S. Wall-based measurement features provide an improved IVUS coronary artery risk assessment when fused with plaque texture-based features during machine learning paradigm. Comput. Biol. Med. 2017, 91, 198–212. [CrossRef]

141. Acharya, U.R.; Faust, O.; Sree, S.V.; Molinari, F.; Suri, J.S. ThyroScreen system: High resolution ultrasound thyroid image characterization into benign and malignant classes using novel combination of texture and discrete wavelet transform. Comput. Methods Programs Biomed. 2011, 107, 233–241. [CrossRef] [PubMed]

142. Pareek, G.; Acharya, U.R.; Sree, S.V.; Swapna, G.; Yantri, R.; Martis, R.J.; Saba, L.; Krishnamurthi, G.; Mallarini, G.; El-Baz, A.; et al. Prostate Tissue Characterization/Classification in 144 Patient Population Using Wavelet and Higher Order Spectra Features from Transrectal Ultrasound Images. Technol. Cancer Res. Treat. 2013, 12, 545–557. [CrossRef]

143. McClure, P.; Elnakib, A.; El-Ghar, M.A.; Khalifa, F.; Soliman, A.; El-Diasty, T.; Suri, J.S.; Elmaghraby, A.; El-Baz, A. In-Vitro and In-Vivo Diagnostic Techniques for Prostate Cancer: A Review. J. Biomed. Nanotechnol. 2014, 10, 2747–2777. [CrossRef]

144. Acharya, U.R.; Saba, L.; Molinari, F.; Guerrero, S.; Suri, J.S. Ovarian tumor characterization and classification: A class of GynScan™ systems. In Proceedings of the 2012 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, San Diego, CA, USA, 28 August–1 September 2012; pp. 4446–4449.

145. Fasano, A.; Cereda, E.; Barichella, M.; Cassani, E.; Ferri, V.; Zecchinelli, A.L.; Pezzoli, G. COVID-19 in Parkinson’s disease patients living in Lombardy, Italy. Mov. Disorder. 2020, 35, 1089–1093. [CrossRef]

146. Mitchell, F. Vitamin-D and COVID-19: Do deficient risk a poorer outcome? Lancet Diabetes Endocrinol. 2020, 8, 570. [CrossRef]

147. De Siqueira, J.V.V.; Almeida, L.G.; Zica, B.O.; Brum, I.B.; Barceló, A.; Galil, A.G.D.S. Impact of obesity on hospitalizations and mortality, due to COVID-19 pandemic: A systematic review. Obes. Res. Clin. Pract. 2020, 14, 398–403. [CrossRef]

148. Ding, H.; Dhma, K.; Lockhart, K.C.; Locascio, J.J.; Hoensing, A.N.; Duong, K.; Trisini-Lipsanopoulos, A.; Hayes, M.T.; Sohur, U.S.; Wills, A.-M.; et al. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology 2013, 81, 1531–1537. [CrossRef] [PubMed]

149. Hribar, C.A.; Cobbold, P.H.; Church, F.C. Potential role of vitamin D in the elderly to resist COVID-19 and to slow progression of Parkinson’s disease. Brain Sci. 2020, 10, 284. [CrossRef] [PubMed]

150. Saba, L.; Agarwal, M.; Patrick, A.; Puvvu, A.; Gupta, S.K.; Carriero, A.; Laird, J.R.; Kitas, G.D.; Johri, A.M.; Balestrieri, A.; et al. Six artificial intelligence paradigms for tissue characterisation and classification of non-COVID-19 pneumonia against COVID-19 pneumonia in computed tomography lung scans. Int. J. Comput. Assist. Radiol. Surg. 2021, 16, 423–434. [CrossRef] [PubMed]
151. De Velasco Oriol, J.; Vallejo, E.E.; Estrada, K.; Tamé Peña, J.G. Disease Neuroimaging Initiative. Benchmarking machine learning models for late-onset Alzheimer’s disease’s prediction from genomic data. BMC Bioinform. 2019, 20, 709. [CrossRef]

152. Da Silva, R.M.; Santos, V.L.d.; Silva, T.V.d.A.; Lins, C.C.d.S.A. Prevalence of temporomandibular joint disorder in people with Parkinson’s disease in a public university hospital. Rev. CEFAC 2019, 21. [CrossRef]

153. Cho, H.-G.; Yoon, J.-H.; Chung, T.-H.; Min, C.; Yoo, D.-M.; Wee, J.-H.; Kang, S.-Y.; Choi, Y.; Hong, S.-J.; Byun, S.-H. Association between Temporomandibular Joint Disorder and Parkinson’s Disease. Brain Sci. 2021, 11, 747. [CrossRef]

154. Moccia, S.; Nucci, L.; Spagnuolo, C.; D’Apuzzo, F.; Piancino, M.G.; Minervini, G. Polyphenols as Potential Agents in the Management of Temporomandibular Disorders. Appl. Sci. 2020, 10, 5305. [CrossRef]

155. Manfredini, D. A better definition of counselling needs to be used to define effectiveness in temporomandibular disorders management. Evid. Based Dent. 2013, 14, 118–119. [CrossRef]

156. Baba, Y.; Higuchi, M.A.; Fukuyama, K.; Abe, H.; Uehara, Y.; Inoue, T.; Yamada, T. Effect of chronic kidney disease on excessive daytime sleepiness in Parkinson disease. Eur. J. Neurol. 2011, 18, 1299–1303. [CrossRef]

157. Moore, S.T.; MacDougall, H.G.; Ondo, W.G. Ambulatory monitoring of freezing of gait in Parkinson’s disease. Neurosci. Methods 2008, 167, 340–348. [CrossRef]

158. Kummer, B.R.; Diaz, I.; Wu, X.; Aaroe, A.E.; Chen, M.L.; Iadecola, C.; Kamel, H.; Navi, B.B. Associations between cerebrovascular risk factors and Parkinson disease. Ann. Neurol. 2019, 86, 572–581. [CrossRef]

159. Shahwar, T.; Zafar, J.; Almogren, A.; Zafar, H.; Rehman, A.U.; Shafiq, M.; Hamam, H. Automated detection of Alzheimer’s via hybrid classical quantum neural networks. Electronics 2022, 11, 721. [CrossRef]

160. Raglione, L.M.; Sorbi, S.; Nacmias, B. Osteoporosis and Parkinson’s disease. Clin. Cases Miner. Bone Metab. 2014, 9, 16. [CrossRef]

161. Invernizzi, M.; Carda, S.; Viscontini, G.S.; Cisari, C. Osteoporosis in Parkinson’s disease. Parkinsonism Relat. Disord. 2009, 15, 339–346. [CrossRef]

162. Wang, X.; Zeng, F.; Jin, W.-S.; Zhu, C.; Wang, Q.-H.; Bu, X.-L.; Luo, H.-B.; Zou, H.-Q.; Pu, J.; Zhou, Z.-H. Comorbidity burden of patients with Parkinson’s disease and Parkinsonism between 2003 and 2012: A multicentre, nationwide, retrospective study in China. Sci. Rep. 2017, 7, 1671. [CrossRef]

163. Brown, E.G.; Chahine, I.M.; Goldman, S.M.; Korell, M.; Mann, E.; Kinel, D.R.; Arnedo, V.; Marek, K.L.; Tanner, C.M. The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease. J. Parkinson’s Dis. 2020, 10, 1365–1377. [CrossRef]

164. Sattar, Y.; Lacey, A.; Akbari, A.; Smith, M.; Pickrell, O.; Lane, E. Association between levodopa and ischemic heart disease. J. Parkinson’s Dis. 2019, 9, 119–126. [CrossRef]

165. Orayj, K.; Lacey, A.; Akbari, A.; Smith, M.; Pickrell, O.; Lane, E. Association between levodopa and ischemic heart disease. J. Parkinson’s Dis. 2019, 9, 119–126. [CrossRef]

166. Shahwar, T.; Zafar, J.; Almogren, A.; Zafar, H.; Rehman, A.U.; Shafiq, M.; Hamam, H. Automated detection of Alzheimer’s via hybrid classical quantum neural networks. Electronics 2022, 11, 721. [CrossRef]

167. Raglione, L.M.; Sorbi, S.; Nacmias, B. Osteoporosis and Parkinson’s disease. Clin. Cases Miner. Bone Metab. 2014, 9, 16. [CrossRef]

168. Rocchi, C.; Pierantozzi, M.; Galati, S.; Chiaravalloti, A.; Pisani, V.; Prosperetti, C.; Lauretti, B.; Bassi, M.S.; Olivola, E.; Schillaci, O. Autonomic function tests and MIBG in Parkinson’s disease: Correlation to disease duration and motor symptoms. JCF Heart Vasc. 2020, 29, 100589. [CrossRef]

169. Hardy, J. Genetic Analysis of Pathways to Parkinson Disease. Neuron 2010, 68, 201–206. [CrossRef]

170. Su, C.; Tong, J.; Wang, F. Mining genetic and transcriptomic data using machine learning approaches in Parkinson’s disease. npj Parkinson’s Dis. 2020, 6, 24. [CrossRef]

171. Shukla, V.; Mishra, S.K.; Pant, H.C. Oxidative stress in neurodegeneration. Adv. Pharmacol. Sci. 2011, 2011, 572634. [CrossRef]

172. Zhao, C.; Zhang, C.; Xing, Z.; Ahmad, Z.; Li, J.-S.; Chang, M.-W. Pharmacological effects of natural Ganoederma and its extracts on neurodegenerative diseases: A comprehensive review. Int. J. Mol. Sci. 2018, 121, 1160–1178. [CrossRef]

173. Yu, J.; Park, S.; Kwon, S.-H.; Ho, C.M.B.; Pyo, C.-S.; Lee, H. AI-based Stroke Disease Prediction System Using Real-Time Electromyography Signals. Appl. Sci. 2020, 10, 6791. [CrossRef]

174. Emma, P.; Bennett, M.R. The role of mitochondrial DNA damage in the development of atherosclerosis. Free Radic. Biol. Med. 2016, 100, 223–230. [CrossRef]

175. Wang, X.; Cao, G.; Ding, D.; Li, F.; Zhao, X.; Wang, J.; Yang, Y. Ferruginol prevents degeneration of dopaminergic neurons by enhancing clearance of α-synuclein in neuronal cells. Fitoterapia 2021, 156, 105066. [CrossRef] [PubMed]

176. Sampedro, F.; Martínez-Horta, S.; Horta-Barba, A.; Grothe, M.J.; Labrador-Espinosa, M.A.; Jesús, S.; Adarmes-Gómez, A.; Carrillo, F.; Puig-Davi, A.; Lora, F.R. Increased homocysteine levels correlate with cortical structural damage in Parkinson’s disease. J. Neurosci. 2022, 43, 120148. [CrossRef] [PubMed]

177. Madamanchi, N.R.; Runge, M.S. Mitochondrial dysfunction in atherosclerosis. Circ. Res. 2007, 100, 460–473. [CrossRef]

178. Frostegard, J.; Haegerstrand, A.; Gidlund, M.; Nilsson, J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 1991, 90, 119–126. [CrossRef]

179. Chirkov, Y.Y.; Nguyen, T.H.; Horowitz, J.D. Impairment of Anti-Aggregatory Responses to Nitric Oxide and Prostacyclin: Mechanisms and Clinical Implications in Cardiovascular Disease. Int. J. Mol. Sci. 2022, 23, 1042. [CrossRef]
206. Halder, A.; Datta, B. COVID-19 detection from lung CT-scan images using transfer learning approach. *Mach. Learn. Sci. Technol.* 2021, 2, 045013. [CrossRef]

207. Jamthikar, A.; Gupta, D.; Khanna, N.N.; Saba, L.; Laird, J.R.; Suri, J.S. Cardiovascular/stroke risk prevention: A new machine learning framework integrating carotid ultrasound image-based phenotypes and its harmonics with conventional risk factors. *Indian Heart J.* 2020, 72, 258–264. [CrossRef]

208. Jamthikar, A.D.; Gupta, D.; Puvvula, A.; Johri, A.M.; Khanna, N.N.; Saba, L.; Mavrogeni, S.; Laird, J.R.; Pareek, G.; Miner, M.; et al. Cardiovascular risk assessment in patients with rheumatoid arthritis using carotid ultrasound B-mode imaging. *Rheumatol. Int.* 2020, 40, 1921–1939. [CrossRef]

209. Jamthikar, A.D.; Gupta, D.; Saba, L.; Khanna, N.N.; Viskovic, K.; Mavrogeni, S.; Laird, J.R.; Sattar, N.; Johri, A.M.; Pareek, G. Artifical intelligence framework for predictive cardiovascular and stroke risk assessment models: A narrative review of integrated approaches using carotid ultrasound. *Comput. Biol. Med.* 2020, 126, 104043. [CrossRef]

210. Murgia, A.; Balestrieri, A.; Crivelli, P.; Suri, J.S.; Conti, M.; Cademartiri, F.; Saba, L. Cardiac computed tomography radiomics: An emerging tool for the non-invasive assessment of coronary atherosclerosis. *Cardiovasc. Diagn. Ther.* 2020, 10, 2005–2017. [CrossRef]

211. Shrivastava, V.K.; Londhe, N.D.; Sonawane, R.S.; Suri, J.S. A novel and robust Bayesian approach for segmentation of psoriasis lesions and its risk stratification. *Comput. Methods Programs Biomed.* 2017, 150, 9–22. [CrossRef]

212. Saba, L.; Sanfilippo, R.; Porcu, M.; Lucatelli, P.; Montisci, R.; Zaccagna, F.; Suri, J.S.; Anzidei, M.; Wintermark, M. Relationship between white matter hyperintensities volume and the circle of Willis configurations in patients with carotid artery pathology. *Eur. J. Radiol.* 2017, 89, 111–116. [CrossRef]

213. Araki, T.; Ikeda, N.; Dey, N.; Chakraborty, S.; Saba, L.; Kumar, D.; Godia, E.C.; Jiang, X.; Gupta, A.; Radeva, P.; et al. A comparative approach of four different image registration techniques for quantitative assessment of coronary artery calcium lesions using intravascular ultrasound. *Comput. Methods Programs Biomed.* 2015, 118, 158–172. [CrossRef]

214. Jain, P.K.; Sharma, N.; Saba, L.; Paraskevas, K.I.; Kalra, M.K.; Johri, A.; Nicolaides, A.N.; Suri, J.S. Automated deep learning-based paradigm for high-risk plaque detection in B-mode common carotid ultrasound scans: An asymptomatic Japanese cohort study. *Int. Angiol.* 2021, 41, 9–23. [CrossRef]

215. Shrivastava, V.K.; Londhe, N.D.; Sonawane, R.S.; Suri, J.S. Reliable and accurate psoriasis disease classification in dermatology images using comprehensive feature space in machine learning paradigm. *Expert Syst. Appl.* 2015, 42, 6184–6195. [CrossRef]

216. Little, B.P. Disease Severity Scoring for COVID-19: A Welcome Semiquantitative Role for Chest Radiography. *Radiology* 2022, 2, 470. [CrossRef]

217. Suri, J.S. Imaging Based Symptomatic Classification and Cardiovascular Stroke Risk Score Estimation. U.S. Patent 13/053,971, 20 October 2011.

218. Khan, A.A.; Shafiq, S.; Kumar, R.; Kumar, J.; Haq, A.U. H3DNN: 3D deep learning based detection of COVID-19 virus using lungs computed tomography. In Proceedings of the 2020 17th International Computer Conference on Wavelet Active Media Technology and Information Processing (ICCWAMTIP), Chengdu, China, 18–21 December 2020; pp. 183–186.

219. Saba, L.; Agarwal, M.; Sanagala, S.; Gupta, S.; Sinha, G.; Johri, A.; Khanna, N.; Mavrogeni, S.; Laird, J.R.; Pareek, G.; et al. Brain MRI-based Wilson disease tissue classification: An optimised deep transfer learning approach. *Electron. Lett.* 2020, 56, 1395–1398. [CrossRef]

220. Suri, J.S.; Puvvula, A.; Majhail, M.; Biswas, M.; Jamthikar, A.D.; Saba, L.; Faa, G.; Singh, I.M.; Oberleitner, R.; Turk, M. Integration of cardiovascular risk assessment with COVID-19 using artificial intelligence. *Rev. Cardiovasc. Med.* 2020, 21, 541–560. [CrossRef]

221. Jamthikar, A.D.; Gupta, D.; Saba, L.; Khanna, N.N.; Araki, T.; Viskovic, K.; Mavrogeni, S.; Laird, J.R.; Pareek, G.; Miner, M.; et al. Cardiovascular/stroke risk predictive calculators: A comparison between statistical and machine learning models. *Cardiovasc. Diagn. Ther.* 2020, 10, 919–938. [CrossRef]

222. Jamthikar, A.D.; Gupta, D.; Johri, A.M.; Mantella, L.E.; Saba, L.; Kolluri, R.; Sharma, A.M.; Viswanathan, V.; Nicolaides, A.; Suri, J.S. Low-Cost Office-Based Cardiovascular Risk Stratification Using Machine Learning and Focused Carotid Ultrasound in an Asian-Indian Cohort. *J. Med. Syst.* 2020, 44, 208. [CrossRef] [PubMed]

223. Molinari, F.; Liboni, W.; Giustetto, P.; Badalamenti, S.; Suri, J.S. Automatic computer-based tracings (act) in longitudinal 2-d ultrasound images using different scanners. *J. Mech. Math. Biol.* 2009, 5, 481–505. [CrossRef]

224. Sudeep, P.; Palanisamy, P.; Rajan, J.; Baradaran, H.; Saba, L.; Gupta, A.; Suri, J.S. Speckle reduction in medical ultrasound images using an unbiased non-local means method. *Biomed. Signal Process. Control* 2016, 28, 1–8. [CrossRef]

225. Petowar, R.J.; Tedla, Y.; Korcarz, C.E.; Tattersall, M.C.; Stein, J.H.; Chesler, N.C.; Gepner, A.D. Carotid Artery Stiffening with Aging: Structural Versus Load-Dependent Mechanisms in MESA (the Multi-Ethnic Study of Atherosclerosis). *Hypertension* 2022, 79, 150–158. [CrossRef]

226. Alqahtani, E.J.; Alshamrani, F.H.; Syed, H.F.; Olatunji, S.O. Classification of Parkinson’s Disease Using NNge Classification Algorithm. In Proceedings of the 2018 21st Saudi Computer Society National Computer Conference (NCC), Riyadh, Saudi Arabia, 25–26 April 2018; pp. 1–7.

227. Naghsh, E.; Sabahi, M.F.; Beheshiti, S. Spatial analysis of EEG signals for Parkinson’s disease stage detection. *Signal Image Video Process.* 2019, 14, 397–405. [CrossRef]
Khatamino, P.; Cantürk, I.; Özyılmaz, L. A deep learning-CNN based system for medical diagnosis: An application on Parkinson’s disease handwriting drawings. In Proceedings of the 2018 6th International Conference on Control Engineering & Information Technology (CEIT), Istanbul, Turkey, 25–27 October 2018.

Hoq, M.; Uddin, M.N.; Park, S. Vocal Feature Extraction-Based Artificial Intelligent Model for Parkinson’s Disease Detection. *Diagnostics* 2021, 11, 1076. [CrossRef]

Kamble, M.; Shrivastava, P.; Jain, M. Digitized spiral drawing classification for Parkinson’s disease diagnosis. *Meas. Sens.* 2021, 16, 100047. [CrossRef]

Akyl, K. Comparing of deep neural networks and extreme learning machines based on growing and pruning approach. *Expert Syst. Appl.* 2020, 140, 112875. [CrossRef]

Khedr, E.M.; el Fetoh, N.A.; Khalifa, H.; Ahmed, M.A.; el Beh, K.M. Prevalence of non motor features in a cohort of Parkinson’s disease patients. *Clin. Neurol. Neurosurg.* 2013, 115, 673–677. [CrossRef]

Mathew, M.J.; Bajju, J. Machine learning technique based parkinson’s disease detection from spiral and voice inputs. *Eur. J. Mol. Clin. Med.* 2020, 7, 2815–2819.

Jo, T.; Nho, K.; Saykin, A.J. Deep Learning in Alzheimer’s Disease: Diagnostic Classification and Prognostic Prediction Using Neuroimaging Data. *Front. Aging Neurosci.* 2019, 11, 220. [CrossRef]

Maitín, A.M.; García-Tejedor, A.J.; Muñoz, J.P.R. Machine Learning Approaches for Detecting Parkinson’s Disease from EEG Analysis: A Systematic Review. *Appl. Sci.* 2020, 10, 8662. [CrossRef]

Poorjam, A.H.; Kavalekalam, M.S.; Shi, L.; Raykov, J.P.; Jensen, J.R.; Little, M.A.; Christensen, M.G. Automatic quality control and enhancement for voice-based remote Parkinson’s disease detection. *Speech Commun.* 2020, 127, 1–16. [CrossRef]

Naseer, A.; Rani, M.; Naz, S.; Razzak, M.I.; Imran, M.; Xu, G. Refining Parkinson’s neurological disorder identification through deep transfer learning. *Neural Comput. Appl.* 2019, 32, 839–854. [CrossRef]

Amin, J.; Sharif, M.; Raza, M.; Saba, T.; Sial, R.; Shad, S.A. Brain tumor detection: A long short-term memory (LSTM)-based learning model. *Neural Comput. Appl.* 2019, 32, 15965–15973. [CrossRef]

An, Y.; Tang, K.; Wang, J. Time-Aware Multi-Type Data Fusion Representation Learning Framework for Risk Prediction of Cardiovascular Diseases. *IEEE ACM Trans. Comput. Biol. Bioinform.* 2021. [CrossRef]

Tan, L.; Yu, K.; Bashir, A.K.; Cheng, X.; Ming, F.; Zhao, L.; Zhou, T. Toward real-time and efficient cardiovascular monitoring for COVID-19 patients by 5G-enabled wearable medical devices: A deep learning approach. *Neural Comput. Appl.* 2021, 1–14. [CrossRef]

Priyanga, P.; Pattankar, V.V.; Sridèvi, S. A hybrid recurrent neural network—Logistic chaos-based whale optimization framework for heart disease prediction with electronic health records. *Comput. Intell.* 2020, 37, 315–343. [CrossRef]

Khanna, N.N.; Maindarkar, M.; Saxena, A.; Ahluwalia, P.; Paul, S.; Srivastava, S.K.; Cuadrado-Godia, E.; Sharma, A.; Omerzu, T.; Saba, L.; et al. Cardiovascular/Stroke Risk Assessment in Patients with Erectile Dysfunction—A Role of Carotid Wall Arterial Imaging and Plaque Tissue Characterization Using Artificial Intelligence Paradigm: A Narrative Review. *Diagnostics* 2022, 12, 1249. [CrossRef]

Kakadiaris, I.A.; Vigkas, M.; Yen, A.A.; Kuznetsova, T.; Budoff, M.; Naghavi, M. Machine Learning Outperforms ACC/AHA CVD Risk Calculator in MESA. *J. Am. Heart Assoc.* 2018, 7, e009476. [CrossRef]

Rava, R.A.; Seymour, S.E.; Snyder, K.V.; Waqas, M.; Davies, J.M.; Levy, E.I.; Siddiqui, A.H.; Ionita, C.N. Automated Collateral Flow Assessment in Patients with Acute Ischemic Stroke Using Computed Tomography with Artificial Intelligence Algorithms. *World Neurosurg.* 2021, 155, e748–e760. [CrossRef]

Unnikrishnan, P.; Kumar, D.K.; Arjunan, S.P.; Kumar, H.; Mitchell, P.; Kawasaki, R. Development of health parameter model for risk prediction of CVD using SVM. *Comput. Math. Methods Med.* 2016, 2016, 3016245. [CrossRef]

Saba, L.; Sanagala, S.S.; Gupta, S.K.; Koppula, V.K.; Laird, J.R.; Viswanathan, V.; Sanches, M.J.; Kitas, G.D.; Johri, A.M.; Sharma, N. A Multicenter Study on Carotid Ultrasound Plaque Tissue Characterization and Classification Using Six Deep Artificial Intelligence Models: A Stroke Application. *IEEE Trans. Instrum. Meas.* 2021, 70, 2505312. [CrossRef]

Jain, P.K.; Sharma, N.; Giannopoulos, A.A.; Saba, L.; Nicolaides, A.; Suri, J.S. Hybrid deep learning segmentation models for atherosclerotic plaque in internal carotid artery B-mode ultrasound. *Comput. Biol. Med.* 2021, 136, 104721. [CrossRef]

Suri, J.S.; Paul, S.; Maindarkar, M.A.; Puvvula, A.; Saxena, S.; Saba, L.; Turk, M.; Laird, J.R.; Khanna, N.N.; Viskovic, K.; et al. Cardiovascular/Stroke Risk Stratification in Parkinson’s Disease Patients Using Atherosclerosis Pathway and Artificial Intelligence Paradigm: A Systematic Review. *Metabolites* 2022, 12, 312. [CrossRef]

Park, E.; Chang, H.-J.; Nam, H.S. Use of machine learning classifiers and sensor data to detect neurological deficit in stroke patients. *J. Med. Internet Res.* 2017, 19, e7092. [CrossRef]

Munjral, S.; Maindarkar, M.; Ahluwalia, P.; Puvvula, A.; Jhamthikar, A.; Jujaray, T.; Suri, N.; Paul, S.; Pathak, R.; Saba, L. Cardiovascular Risk Stratification in Diabetic Retinopathy via Atherosclerotic Pathway in COVID-19/Non-COVID-19 Frameworks Using Artificial Intelligence Paradigm: A Narrative Review. *Diagnostics* 2022, 12, 1234. [CrossRef]

El-Baz, A.; Gimel’farb, G.; Suri, J.S. *Stochastic Modeling for Medical Image Analysis*; CRC Press: Boca Raton, FL, USA, 2015.

Zimmerman, A.; Kalra, D. Usefulness of machine learning in COVID-19 for the detection and prognosis of cardiovascular complications. *Rev. Cardiovasc. Med.* 2020, 21, 345–352. [CrossRef]

Handy, A.; Wood, A.; Sudlow, C.; Tomlinson, C.; Kee, F.; Thygesen, J.H.; Mamouei, M.; Sofat, R.; Dobson, R.; Ip, H.Y.S. A nationwide deep learning pipeline to predict stroke and COVID-19 death in atrial fibrillation. *medRxiv* 2021. [CrossRef]
254. Bergamaschi, L.; D’Angelo, E.C.; Paolillo, P.; Toniolo, S.; Fabrizio, M.; Angeli, F.; Donati, F.; Magnani, I.; Rinaldi, A.; Bartoli, L.; et al. The value of ECG changes in risk stratification of COVID-19 patients. *Ann. Noninvasive Electrocardiol.* 2021, 26, e12815. [CrossRef]

255. Wodzinski, M.; Skalski, A.; Hemmerling, D.; Orozco-Arroyave, J.R.; Nöth, E. Deep learning approach to Parkinson’s disease detection using voice recordings and convolutional neural network dedicated to image classification. In Proceedings of the 2019 41st Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), Berlin, Germany, 23–27 July 2019; pp. 717–720. [CrossRef] [PubMed]

256. Konstantonis, G.; Singh, K.V.; Sfikakis, P.P.; Jamthikar, A.D.; Kitas, G.D.; Gupta, S.K.; Saba, L.; Verrou, K.; Khanna, N.N.; Ruzsa, Z. Cardiovascular disease detection using machine learning and carotid/femoral arterial imaging frameworks in rheumatoid arthritis patients. *Rheumatol. Int.* 2022, 42, 215–239. [CrossRef] [PubMed]

257. Jamthikar, A.; Gupta, D.; Khanna, N.N.; Araki, T.; Saba, L.; Nicolaides, A.; Sharma, A.; Omerzu, T.; Suri, H.S.; Gupta, A. A special report on changing trends in preventive stroke/cardiovascular risk assessment via B-mode ultrasonography. *Cogn. Inform. Comput. Model. Cogn. Sci.* 2020, 2, 291–318.

258. Kotsis, V.; Jamthikar, A.D.; Araki, T.; Laird, J.R.; Giannopoulos, A.A.; Saba, L.; Suri, H.S.; Mavrogeni, S.; Kitas, G.D. Echolucency-based phenotype in carotid atherosclerosis disease for risk stratification of diabetes patients. *Diabetes Res. Clin. Pract.* 2018, 143, 322–331. [CrossRef] [PubMed]

259. Khanna, N.N.; Jamthikar, A.D.; Araki, T.; Gupta, D.; Piga, M.; Saba, L.; Carcassi, C.; Nicolaides, A.; Laird, J.R.; Suri, H.S. Nonlinear model for the carotid artery disease 10-year risk prediction by fusing conventional cardiovascular factors to carotid ultrasound image phenotypes: A Japanese diabetes cohort study. *Echocardiography* 2019, 36, 345–361. [CrossRef] [PubMed]

260. Khanna, N.N.; Jamthikar, A.; Gupta, D.; Nicolaides, A.; Araki, T.; Saba, L.; Cuadrado-Godia, E.; Sharma, A.; Omerzu, T.; Suri, H.S.; et al. Performance evaluation of 10-year ultrasound image-based stroke/cardiovascular (CV) risk calculator by comparing against ten conventional CV risk calculators: A diabetic study. *Comput. Biol. Med.* 2019, 105, 125–143. [CrossRef]

261. Khanna, N.N.; Jamthikar, A.D.; Gupta, D.; Araki, T.; Piga, M.; Saba, L.; Carcassi, C.; Nicolaides, A.; Laird, J.R.; Suri, H.S.; et al. Effect of carotid image-based phenotypes on cardiovascular risk calculator: AECR51.0. *Med. Biol. Eng. Comput.* 2019, 57, 1553–1566. [CrossRef]

262. Cuadrado-Godia, E.; Jamthikar, A.; Gupta, D.; Khanna, N.N.; Araki, T.; Maniruzzaman; Saba, L.; Nicolaides, A.; Sharma, A.; Omerzu, T; et al. Ranking of stroke and cardiovascular risk factors for an optimal risk calculator design: Logistic regression approach. *Comput. Biol. Med.* 2019, 108, 182–195. [CrossRef]

263. Venetsanopoulou, A.I.; Voulgaris, P.V.; Drosos, A.A. Hyperlipidemia and rheumatoid arthritis. In *Cholesterol*; Academic Press: Cambridge, MA, USA, 2022; pp. 969–997.

264. Jamthikar, A.; Gupta, D.; Cuadrado-Godia, E.; Puvvula, A.; Khanna, N.N.; Saba, L.; Viskovic, K.; Mavrogeni, S.; Turk, M.; Laird, J.R. Ultrasound-based stroke/cardiovascular risk stratification using Framingham Risk Score and ASCVD Risk Score based on Integrated Vascular Age instead of Chronological Age: A multi-ethnic study of Asian Indian, Caucasian, and Japanese cohorts. *Cardiovasc. Diagn. Ther.* 2020, 10, 939. [CrossRef]

265. Saba, L.; Jamthikar, A.; Gupta, D.; Khanna, N.N.; Viskovic, K.; Suri, H.S.; Gupta, A.; Mavrogeni, S.; Turk, M.; Laird, J.R. Global perspective on carotid intima-media thickness and plaque: Should the current measurement guidelines be revisited? *Int. Angiol.* 2020, 38, 451–465. [CrossRef]

266. Puvvula, A.; Jamthikar, A.D.; Gupta, D.; Khanna, N.N.; Porcu, M.; Saba, L.; Viskovic, K.; Ajuluchukwu, J.N.; Gupta, A.; Mavrogeni, S. Morphological carotid plaque area is associated with glomerular filtration rate: A study of south asian indian patients with diabetes and chronic kidney disease. *Angiology* 2020, 71, 520–535. [CrossRef]

267. Suri, J.S.; Viswanathan, V.; Jamthikar, A.D.; Gupta, D.; Shanu, P.; Puvvula, A.; Khanna, N.N.; Saba, L.; Omerzum, T.; Viskovic, K.; et al. Low-cost preventive screening using carotid ultrasound in patients with diabetes. *Front. Biosci.* 2020, 25, 1132–1171. [CrossRef]

268. Yan, Y.; Zhang, J.-W.; Zang, G.-Y.; Pu, J. The primary use of artificial intelligence in cardiovascular diseases: What kind of potential role does artificial intelligence play in future medicine? *J. Geriatr. Cardiol.* 2019, 16, 585–591. [CrossRef]

269. Aljameel, S.S.; Khan, I.U.; Ashlam, N.; Adjabi, M.; Alsalmi, E.S. Machine Learning-Based Model to Predict the Disease Severity and Outcome in COVID-19 Patients. *Sci. Program.* 2021, 2021, 5587188. [CrossRef]

270. Mouridsen, K.; Thurner, P.; Zaharchuk, G. Artificial Intelligence Applications in Stroke. *Stroke* 2020, 51, 2573–2579. [CrossRef]

271. Paul, S.; Maindarkar, M.; Saxena, S.; Saba, L.; Turk, M.; Kalra, M.; Krishnan, P.R.; Suri, J.S. Bias Investigation in Artificial Intelligence Systems for Early Detection of Parkinson’s Disease: A Narrative Review. *Diagnostics* 2022, 12, 166. [CrossRef]

272. Suri, J.S.; Bhagawati, M.; Paul, S.; Protoporos, A.; Sifakis, P.P.; Kitas, G.D.; Khanna, N.N.; Ruzsa, Z.; Sharma, A.M.; Saxena, S.; et al. Understanding the bias in machine learning systems for cardiovascular disease risk assessment: The first of its kind review. *Comput. Biol. Med.* 2022, 142, 105204. [CrossRef]

273. Suri, J.S.; Agarwal, S.; Jena, B.; Saxena, S.; El-Baz, A.; Agarwal, V.; Kalra, M.K.; Saba, L.; Viskovic, K.; Fatemi, M.; et al. Five Strategies for Bias Estimation in Artificial Intelligence-based Hybrid Deep Learning for Acute Respiratory Distress Syndrome COVID-19 Lung Infected Patients using AP(ai)Bias 2.0: A Systematic Review. *IEEE Trans. Instrum. Meas.* 2022. [CrossRef]

274. El-Baz, A.; Suri, J.S. *Big Data in Multimodal Medical Imaging*; CRC Press: Boca Raton, FL, USA, 2019.

275. Murray, C.J.; Lopez, A.D. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. *Lancet* 1997, 349, 1498–1504. [CrossRef]
276. Tandel, G.S.; Biswas, M.; Kakde, O.G.; Tiwari, A.; Suri, H.S.; Turk, M.; Laird, J.R.; Asare, C.K.; Ankrah, A.A.; Khanna, N.N.; et al. A Review on a Deep Learning Perspective in Brain Cancer Classification. *Cancers* **2019**, *11*, 111. [CrossRef]

277. Willmen, T.; Völkel, L.; Ronicke, S.; Hirsch, M.C.; Kaufeld, J.; Rychlik, R.P.; Wagner, A.D. Health economic benefits through the use of diagnostic support systems and expert knowledge. *BMC Health Serv. Res.* **2021**, *21*, 947. [CrossRef]

278. Mital, S.; Nguyen, H.V. Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening. *BMC Cancer* **2022**, *22*, 501. [CrossRef]

279. Areia, M.; Mori, Y.; Correale, L.; Repici, A.; Brethauer, M.; Sharma, P.; Taveira, F.; Spadaccini, M.; Antonelli, G.; Ebigbo, A.; et al. Cost-effectiveness of artificial intelligence for screening colonoscopy: A modelling study. *Lancet Digit. Health* **2022**, *4*, e436–e444. [CrossRef]

280. Morrison, S.L.; Dukhovny, D.; Chan, R.P.; Chiang, M.F.; Campbell, J.P. Cost-effectiveness of Artificial Intelligence–Based Retinopathy of Prematurity Screening. *JAMA Ophthalmol.* **2022**, *140*, 401. [CrossRef] [PubMed]

281. Bao, H.; Zhang, X.; Bi, H.; Zhao, Y.; Fang, L.; Wang, H.; Wang, L. How Can a High-Performance Screening Strategy Be Determined for Cervical Cancer Prevention? Evidence From a Hierarchical Clustering Analysis of a Multicentric Clinical Study. *Front. Oncol.* **2022**, *12*, 816789. [CrossRef]

282. Hoshida, Y.; Fuchs, B.C.; Tanabe, K.K. Prevention of hepatocellular carcinoma: Potential targets, experimental models, and clinical challenges. *Curr. Cancer Drug Targets* **2012**, *12*, 1129–1159.

283. Lee, J.; Choi, W.; Kim, J. A Cost-Effective CNN-LSTM-Based Solution for Predicting Faulty Remote Water Meter Reading Devices in AMI Systems. *Sensors* **2021**, *21*, 6229. [CrossRef]

284. World Health Organization. Cardiovascular Diseases (CVDs). 2017. Available online: [http://www.who.int/mediacentre/factsheets/fs317/en.ed](http://www.who.int/mediacentre/factsheets/fs317/en.ed) (accessed on 11 May 2022).

285. Suri, J.S.; Agarwal, S.; Chabert, G.L.; Carriero, A.; Pasche, A.; Danna, P.S.C.; Saba, L.; Mehmedović, A.; Faa, G.; Singh, I.M.; et al. COVLIAS 1.0 lesion vs. MedSeg: An Artificial Intelligence Framework for Automated Lesion Segmentation in COVID-19 Lung Computed Tomography Scans. *Diagnostics* **2022**, *12*, 1283. [CrossRef]

286. Agarwal, M.; Agarwal, S.; Saba, L.; Chabert, G.L.; Gupta, S.; Carriero, A.; Pasche, A.; Danna, P.; Mehmedovic, A.; Faa, G.; et al. Eight pruning deep learning models for low storage and high-speed COVID-19 computed tomography lung segmentation and heatmap-based lesion localization: A multicenter study using COVLIAS 2.0. *Comput. Biol. Med.* **2022**, *146*. [CrossRef]

287. Hallows, R.; Glazier, L.; Katz, M.; Aznar, M.; Williams, M. Safe and Ethical Artificial Intelligence in Radiotherapy—Lessons Learned From the Aviation Industry. *Clin. Oncol.* **2021**, *34*, 99–101. [CrossRef] [PubMed]

288. Das, S.; Nayak, G.; Saba, L.; Kalra, M.; Suri, J.S.; Saxena, S. An artificial intelligence framework and its bias for brain tumor segmentation: A narrative review. *Comput. Biol. Med.* **2022**, *143*, 105273. [CrossRef] [PubMed]

289. Pablo, R.-G.J.; Roberto, D.-P.; Victor, S.-U.; Isabel, G.-R.; Paul, C.; Elizabeth, O.-R. Big data in the healthcare system: A synergy with artificial intelligence and blockchain technology. *J. Integr. Bioinform.* **2021**, *19*. [CrossRef] [PubMed]

290. Munir, K.; Elahi, H.; Farooq, M.U.; Ahmed, S.; Frezza, F.; Rizzi, A. Detection and screening of COVID-19 through chest computed tomography radiographs using deep neural networks. In *Data Science for COVID-19*; Academic Press: Cambridge, MA, USA, 2021; pp. 63–73.

291. Acharya, U.R.; Mookiah, M.R.K.; Sree, S.V.; Yanti, R.; Martis, R.J.; Saba, L.; Molinari, F.; Guerriero, S.; Suri, J.S. Evolutionary Algorithm-Based Classifier Parameter Tuning for Automatic Ovarian Cancer Tissue Characterization and Classification. *Ultraschall Med. Eur. J. Ultrasound* **2012**, *35*, 237–245. [CrossRef] [PubMed]

292. Sanagala, S.S.; Nicolaides, A.; Gupta, S.K.; Kopppula, V.K.; Saba, L.; Agarwal, S.; Johri, A.M.; Kalra, M.S.; Suri, J.S. Ten Fast Transfer Learning Models for Carotid Ultrasound Plaque Tissue Characterization in Augmentation Framework Embedded with Heatmaps for Stroke Risk Stratification. *Diagnostics* **2021**, *11*, 2109. [CrossRef] [PubMed]